

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
06 August 2020 (06.08.2020)



(10) International Publication Number
WO 2020/156982 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61P 35/00 (2006.01)
A61K 31/53 (2006.01)

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2020/051884

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

27 January 2020 (27.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19154781.9 31 January 2019 (31.01.2019) EP

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(71) Applicants: BAYER AKTIENGESELLSCHAFT

[DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). BAYER PHARMA AKTIENGESELLSCHAFT [DE/DE]; Müllerstr. 178, 13353 Berlin (DE).

Published:

— with international search report (Art. 21(3))

(72) Inventors: GRIES, Jörg; August-Macke-Weg 34, 42781


Haan (DE). PLATZEK, Johannes; Grottkauer Str. 55, 12621 Berlin (DE). HÄSELHOFF, Claus-Christian; Wielandstr.50, 45968 Gladbeck (DE). LOVIS, Kai; Jahnstr. 109A, 40215 Düsseldorf (DE).

(74) Agent: BIP PATENTS; Alfred-Nobel-Str. 10, 40789 Monheim am Rhein NRW (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: THE MONOHYDRATE OF ROGARATINIB HYDROCHLORIDE AND SOLID STATES THEREOF



(III)

(57) Abstract: Compound (III) which is the crystalline form of [4-{4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothio-phen-2-yl)pyrrolo[2, -f] [1,2,4]triazin-7-yl}methyl}piperazin-2-one hydrochloride] which is the monohydrate, processes for its preparation, pharmaceutical compositions comprising it and its use in the control of disorders, including cancer.



WO 2020/156982 A1

THE MONOHYDRATE OF ROGARATINIB HYDROCHLORIDE AND SOLID STATES THEREOF

5 **Background of the invention**

There are many ways how cancers can arise which is one of the reasons why their therapy is difficult. One way that transformation of cells can occur is following a genetic alteration. The completion of the human genome project showed genomic instability and heterogeneity of human cancer genes. Recent strategies to identify these genetic alterations sped up the process of cancer-gene discovery.

10 Gene abnormality can, for instance, lead to the overexpression of proteins, and hence to a non-physiological activation of these proteins. One family of proteins from which a number of oncoproteins derive are tyrosine kinases and in particular receptor tyrosine kinases (RTKs). In the past two decades, numerous avenues of research have demonstrated the importance of RTK-mediated signaling in adverse cell growth leading to cancer. In recent years, promising results have been

15 achieved in the clinic with selective small-molecule inhibitors of tyrosine kinases as a new class of anti-tumorigenic agents [Swinney and Anthony, *Nature Rev. Drug Disc.* 10 (7), 507-519 (2011)].

Fibroblast growth factors (FGFs) and their receptors (FGFRs) form part of a unique and diverse signaling system which plays a key role in a variety of biological processes which encompass various aspects of embryonic development and adult pathophysiology [Itoh and Ornitz, *J. Biochem.* 149 (2),

20 121-130 (2011)]. In a spatio-temporal manner, FGFs stimulate through FGFR binding a wide range of cellular functions including migration, proliferation, differentiation, and survival.

The FGF family comprises 18 secreted polypeptidic growth factors that bind to four highly conserved receptor tyrosine kinases (FGFR-1 to -4) expressed at the cell surface. In addition, FGFR-5 can bind to FGFs but does not have a kinase domain, and therefore is devoid of intracellular signaling. The

25 specificity of the ligand/receptor interaction is enhanced by a number of transcriptional and translational processes which give rise to multiple isoforms by alternative transcriptional initiation, alternative splicing, and C-terminal truncations. Various heparan sulfate proteoglycans (e.g. syndecans) can be part of the FGF/FGFR complex and strongly influence the ability of FGFs to induce signaling responses [Polanska *et al.*, *Developmental Dynamics* 238 (2), 277-293 (2009)].

30 FGFRs are cell surface receptors consisting of three extracellular immunoglobulin-like domains, a single-pass transmembrane domain, and an intracellular dimerized tyrosine kinase domain. Binding of FGF bring the intracellular kinases into close proximity, enabling them to transphosphorylate each other. Seven phosphorylation sites have been identified (e.g., in FGFR-1 Tyr463, Tyr583, Tyr585, Tyr653, Tyr654, Tyr730, and Tyr766).

35 Some of these phosphotyrosine groups act as docking sites for downstream signalling molecules which themselves may also be directly phosphorylated by FGFR, leading to the activation of multiple signal transduction pathways. Thus, the MAPK signaling cascade is implicated in cell growth and

differentiation, the PI3K/Akt signaling cascade is involved in cell survival and cell fate determination, while the PI3K and PKC signaling cascades have a function in the control of cell polarity. Several feedback inhibitors of FGF signaling have now been identified and include members of the Spry (Sprouty) and Sef (similar expression to FGF) families. Additionally, in certain conditions, FGFR is released from pre-Golgi membranes into the cytosol. The receptor and its ligand, FGF-2, are co-transported into the nucleus by a mechanism that involves importin, and are engaged in the CREB-binding protein (CBP) complex, a common and essential transcriptional co-activator that acts as a gene activation gating factor. Multiple correlations between the immunohistochemical expression of FGF-2, FGFR-1 and FGFR-2 and their cytoplasmic and nuclear tumor cell localizations have been observed. For instance, in lung adenocarcinomas this association is also found at the nuclear level, emphasizing an active role of the complex at the nucleus [Korc and Friesel, *Curr. Cancer Drugs Targets* 5, 639-651 (2009)].

FGFs are widely expressed in both developing and adult tissues and play important roles in a variety of normal and pathological processes, including tissue development, tissue regeneration, angiogenesis, neoplastic transformation, cell migration, cellular differentiation, and cell survival. Additionally, FGFs as pro-angiogenic factors have also been implicated in the emerging phenomenon of resistance to vascular endothelial growth factor receptor-2 (VEGFR-2) inhibition [Bergers and Hanahan, *Nat. Rev. Cancer* 8, 592-603 (2008)].


Recent oncogenomic profiles of signaling networks demonstrated an important role for aberrant FGF signaling in the emergence of some common human cancers [Wesche *et al.*, *Biochem. J.* 437 (2), 199-213 (2011)]. Ligand-independent FGFR constitutive signaling has been described in many human cancers, such as brain cancer, head and neck cancer, gastric cancer and ovarian cancer. FGFR-mutated forms as well as FGFR-intragenic translocations have been identified in malignancies such as myeloproliferative diseases. Interestingly, the same mutations discovered to be the cause of many developmental disorders are also found in tumor cells (e.g., the mutations found in achondroplasia and thanatophoric dysplasia, which cause dimerization and thus constitutive activation of FGFR-3, are also frequently found in bladder cancer). A mutation that promotes dimerization is just one mechanism that can increase ligand-independent signaling from FGFRs. Other mutations located inside or outside of the kinase domain of FGFRs can change the conformation of the domain giving rise to permanently active kinases.

Amplification of the chromosomal region 8p11-12, the genomic location of *FGFR-1*, is a common focal amplification in breast cancer and occurs in approximately 10% of breast cancers, predominantly in oestrogen receptor-positive cancers. *FGFR-1* amplifications have also been reported in non-small cell lung squamous carcinoma and are found at a low incidence in ovarian cancer, bladder cancer and rhabdomyosarcoma. Similarly, approximately 10% of gastric cancers show *FGFR-2* amplification, which is associated with poor prognosis, diffuse-type cancers. Moreover, multiple single nucleotide polymorphisms (SNPs) located in *FGFR-1* to -4 were found to correlate with an increased risk of developing selective cancers, or were reported to be associated with poor prognosis


(e.g., FGFR-4 G388R allele in breast cancer, colon cancer and lung adenocarcinoma). The direct role of these SNPs to promote cancer is still controversial.

Potent FGFR inhibitors of general formula (I) were identified in WO 2013/087578, published 20 June, 2013:

- 5 6,7-disubstituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives of the general formula (A)



More particularly, a compound of the formula (I)



(I)

4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f]-[1,2,4]-triazin-7-yl}methyl}piperazin-2-one

or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which serves for production of medicaments and for production of medicaments for treatment and/or prophylaxis of proliferative disorders, such as cancer and tumor diseases, is a particularly potent FGFR inhibitor.


4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f]-[1,2,4]-triazin-7-yl}methyl}piperazin-2-one has been given the INN ROGARATINIB.

Rogaratnib has valuable pharmacological properties and can be used for the prevention and treatment of disorders in humans and other mammals.

Rogaratnib is a potent inhibitor of the activity or expression of receptor tyrosine kinases, particularly of the FGFR kinases, and most notably of the FGFR-1 and FGFR-3 kinases. In certain embodiments, the disorders relating to the activity of FGFR kinases are proliferative disorders, in particular cancer and tumor diseases.

Synthesis of (I) has been described in WO 2013/087578 by two routes, which are illustrated in the following schemes. A synthetic route from WO 2013/087578 is described in Scheme 1:


15 Scheme 1



20

An alternate route from WO 2013/087578 leading to (I) is illustrated in scheme 2.


Scheme 2:



5


Preparation of 4-aminopyrrolo[2,1-f][1,2,4]triazine-6-carbonitrile is described in WO2007/064883 and is depicted in Scheme 3.

Scheme 3:



A generic route for the preparation of compounds of the formula (I) is described in WO 2013/087578,
5 but has not been applied to the synthesis of (I). It is depicted in scheme 4.


Scheme 4:




10

Preparation of intermediate (VII) has been described in WO 2013/087578 according to this generic route by the sequence shown in the following scheme 5. The total yield of this 4 step process from (IX) to compound (VII) was 6%, only and made use of 4 chromatographic purifications, which are unfavorable from an economic point of view. Further conversion of compound (VII) to (I) has not
15 been described in prior art.


Scheme 5:






The preparation of (IX) has been described in WO 2007/064883 by the reaction sequence which is illustrated in Scheme 6.

Scheme 6:



10

The di-hydrochloride of 4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl}methyl}piperazin-2-one (XIV) and its preparation process was disclosed first in WO 2013/087578A1 (Bayer)



20 The preparation of the di-hydrochloride was described in WO 2013/087578A1 (Bayer) example II. The only suitable method for obtaining this compound is by using HCl in dioxane. Other attempts to

get the di-hydrochloride, e.g. by treatment with concentrated HCl in various solvents, results in non-soluble materials (highly hygroscopic; gums etc.). From a regulatory aspect, dioxane is not a favorable solvent to use in the final step of a synthesis, because the limit for residual solvent is very low. Also, ring-opened by-products from the reaction of HCl with dioxane can result in genotoxic impurities which have to be reduced to ppm level.


The di-hydrochloride is very hygroscopic and loses HCl on standing in the air (i.e., it is chemically unstable), which results in undefined mixtures of various hydrates and hydrochloride stoichiometry. It is very difficult to handle the di-hydrochloride on scale, especially on production scale.

10

The disadvantageous properties of the di-hydrochloride result in problems for large-scale preparations of the solid form of 4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl}methyl}piperazin-2-one. Thus, a need exists for stable salts and crystalline forms of rogaratinib.

15 While the processes disclosed by the prior art are *per se* effective for preparing the compound of the formula (I) and its synthesis intermediates, factors such as purity, product yields, process efficiency, safety and economy are very significant for an industrial scale process of a pharmaceutical product. A need also exists for an efficient process with high yield for preparation of compound of the formula (I) and its salts and various crystalline forms.

20 It is an object of the present invention to provide an efficient process with high yield for preparation of the compound of the formula (I)



25

or a pharmaceutically acceptable salt, hydrate, or solvate thereof (rogaratinib).


It is an object of the present invention to provide a process for preparing the compound of the formula (I), in industrial scale (kilogram to metric tons range), which satisfies the criteria which apply in production and provides improvements in purity, environmental compatibility, industrial employability, safety aspects and volume yield. Purity and safety aspects are to be considered particularly relevant for the preparation of pharmaceuticals.

It is an object of the present invention to provide (I) in a solid state form which shows superior qualities compared to the known dihydrochloride.


The present invention solves those problems as described below.

Summary of the Invention

10 The present invention relates to compound (III)



which is the monohydrate of the monochloride of compound (I)




The present invention also relates to a pharmaceutical composition comprising monohydrate of the monochloride of compound I which is compound (III) and optionally further pharmaceutically acceptable excipients.

The present invention also relates to a process for preparing the compound of the formula (III), which is the monochloride monohydrate of compound (I), the process comprising suspending or dissolving (I) in the presence of a solvent and treating the resulting solution with an acid or acid precursor.


Detailed Description of the Invention

4-{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl}piperazin-2-one corresponds to the formula (I), [4-{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl}piperazin-2-one hydrochloride] corresponds to the compound of formula (II) and its monohydrate corresponds to the formula (III).




20

(I)



(II)




(III)

5

The inventive preparation of the compound of the formula (III), which is the monochloride monohydrate of compound (I) in its advantageous crystalline form, which previously has not been described, is shown in the following scheme:

10 Scheme 7: Synthesis of (III)



One aspect of the present invention is an efficient process with high yield for preparation of rogaratinib, which is obtained in very high purity without using chromatographic techniques. Furthermore, (I) is converted to its hydrochloride salt (II), more specifically as its crystalline monohydrate form with the chemical composition as in formula (III), having advantageous properties for using it as pharmaceutical ingredient.

4-[[4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl]piperazin-2-one-mono-hydrochloride corresponds to the compound of formula (II).

The present invention provides the compound of formula (II) in a solid state which is

- is physically and chemically stable
- can be formulated as tablet without an undue burden
- can be prepared in a reproducible manner, also on large scale
- is easy to isolate, either by centrifuge or by filtration in high chemical purity
- is easy to dry on scale
- shows better solubility than the free base
- is less hygroscopic than the Di-hydrochloride (prior art)
- has good handling properties on scale, e.g., less electrostatic than the dihydrochloride
- is easy to micronize and in high yields
- is storable over a long period of time (important if you have only defined production slots over the year)

It has now been found that the monohydrate of the monohydrochloride of 4-{{[4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl}piperazin-2-one [A] provides the benefits described above.

Along with the preferred new monohydrate form, several other new hydrates were found. Compound
5 of formula (II) can exist in four different hydrate forms and an amorphous form. A $\frac{3}{4}$ -hydrate (2.6 % water), a monohydrate (3.5 % water), a dihydrate (6.7 % water) and a trihydrate (9.7 % water) were found. The $\frac{3}{4}$ -hydrate, the trihydrate as well as the amorphous form changed into the monohydrate during storage at high humidity. The dihydrate transformed into the monohydrate during storage in a closed vessel within two weeks. The following hydrate forms of compound II of the compound of
10 formula (I) have been identified which are:

1. Monohydrate (one equ. water): A (Compound (III))
2. Dihydrate (two equ. water): B
3. Trihydrate (three equ. water): C
4. $\frac{3}{4}$ Hydrate (0.75 equ. Water): D
- 15 5. Amorphous Form: E

All together – the hydrate forms and the amorphous form – are different solid forms of the compound of formula (II).

Monohydrate of the compound of the formula (II) is preferred form and is referred to herein as compound (III). Surprisingly, compound (III) shows beneficial properties over the other solid forms of the
20 compound of formula (II) with regard to:

- physical stability: Storage at 25 and 50°C for 12 month show no changes in stability;
- chemical stability: The monohydrate is chemically stable during storage for several years
- can be formulated as a tablet without undue burden by the process steps of dry blending, wet granulation, drying and dry milling, final blending, tablet compression and coating;
- 25 - there is no interaction observed with the tablet ingredients. The monohydrate form is stable in the tablet matrix and does not change during storage (see Table 5) - compatibility over other ingredients is given;
- 30 - can be prepared in a reproducible manner, also on large scale. This was demonstrated in several pilot plant campaigns, where > 100 kg of drug substance were prepared;

- is easy to isolate, either by centrifuge or by filtration. This was shown in several pilot plant campaigns. Isolation of monohydrate form is done without technical problems;
- is isolated in high chemical purity and high chemical yield. This was shown in several pilot plant campaigns. The quality of the material is excellent and confirms the specification;
- 5 - is easy to dry on scale. This was demonstrated in several pilot plant campaigns. The material can easily be dried under vacuum without significant losses of HCl and water. HCl and water values comply with the specification;
- is more soluble than the free base. The monohydrate form has significantly better solubility in water. This results in an enhanced bioavailability;
- 10 - is less hygroscopic than the di-hydrochloride. Moisture sorption tests (experimental part 4.4.) were performed with the monohydrate form. The compound was stored for 12 month at 15 % r.h. , 85 % r.h and 97 % r.h. (r.h. = relative humidity), no uptake of water was seen which clearly demonstrates that the monohydrate form is not hygroscopic. It is interesting to mention, that all other forms change into the monohydrate form under storage conditions
15 (see Table 4.)
- has good handling properties on scale and is less electrostatic. The monohydrate form is easily to handle in bulk. Weighing and pouring of the compound can easily be performed, no electrostatic properties were observed;
- is easy to micronize and in high yields. Micronization of large batches were performed with
20 yields generally > 95 % (th.). No problems during micronization were observed. The target particle size can easily be obtained in a reproducible manner;
- is storable over a long period of time (important if you have only defined production slots over the year). Stability data demonstrate that the monohydrate compound form is very stable during storage;
- 25 - the habitus of the crystals is acceptable in terms of filtration and isolation. Filtration times are very short which is a great advantage for handling in the pilot plant.

The monohydrate form (III) is therefore more suitable and preferred over the other solid forms of the compound of formula I for production on a large scale.

- 30 In particular, the compound of the formula (III) reduces any undesired conversion into another form of the compound of formula (II) and an associated change in the properties as described above is minimized. This should increase the safety and quality of preparations and formulations comprising of the compound of the formula (II) and the risk to the patient is reduced.

A pharmaceutical composition according to the present invention comprises compound (III) and optionally further pharmaceutically acceptable excipients.

Preferably, the pharmaceutical composition comprises compound (III), and no significant fractions of another form of the compound of the formula (II), and optionally further pharmaceutically acceptable excipients. More preferably, the pharmaceutical composition comprises more than 85 percent by weight, more preferably more than 90 percent by weight, most preferably more than 95 percent by weight, of compound (III) related to the total amount of all forms of the compound of the formula (II) present in the composition.

The different forms of the compound of formula (II) can be distinguished by X-ray powder diffraction, differential scanning calorimetry (DSC), IR-, Raman-, NIR-, FIR- and ¹³C-solid-state-NMR-spectroscopy.

The compound (III) of the compound of formula (I) can be characterized unambiguously by an X-Ray powder diffractogram (at 25°C and with Cu-K alpha 1 as radiation source) which displays at least the following reflections: 9.3, 10.6, 13.3, preferably at least the following reflections: 9.3, 10.6, 13.3, 20.7, 23.3, more preferably at least the following reflections: 9.3, 10.6, 11.4, 13.3, 20.7, 23.3, 26.0, most preferably at least the following reflections: 6.8, 9.3, 10.6, 11.4, 13.3, 20.7, 23.3, 24.6, 26.0, 27.6, each quoted as 2 Θ value \pm 0.2°.

The compound (III) can also be characterized unambiguously by the X-Ray powder diffractogram (at 25°C and with Cu-K alpha 1 as radiation source) as shown in Figure 1.


The dihydrate form [B] of the compound of formula (II) can be characterized unambiguously by a X-Ray powder diffractogram (at 25°C and with Cu-K alpha 1 as radiation source) which displays at least the following reflections: 6.7, 13.9, 14.5, preferably at least the following reflections: 6.7, 11.7, 13.5, 13.9, 14.5, more preferably at least the following reflections: 6.2, 6.7, 11.7, 12.6, 13.5, 13.9, 17.9, most preferably at least the following reflections: 6.2, 6.7, 11.7, 12.6, 13.5, 13.9, 14.5, 16.4, 17.9, 25.9, each quoted as 2 Θ value \pm 0.2°. The compound of formula (I) in the dihydrate form [B] can also be characterized unambiguously by the X-Ray powder diffractogram (at 25°C and with Cu-K alpha 1 as radiation source) as shown in Figure 2.

The trihydrate form [C] of the compound of formula (II) can be characterized unambiguously by a X-Ray powder diffractogram (at 25°C and with Cu-K alpha 1 as radiation source) which displays at least the following reflections: 6.8, 12.9, 14.6, preferably at least the following reflections: 6.8, 7.6, 12.9, 14.6, 26. , more preferably at least the following reflections: 6.8, 7.6, 11.2, 12.9, 14.6, 22. , 26.5, most preferably at least the following reflections: 6.8, 7.6, 11.2, 12.9, 13.5, 14.6, 17.4, 22.5, 23.3, 26.5, each quoted as 2 Θ value \pm 0.2°. The compound of formula (I) in the trihydrate form [C] can also be characterized unambiguously by the X-Ray powder diffractogram (at 25°C and with Cu-K alpha 1 as radiation source) as shown in Figure 3.

The $\frac{3}{4}$ -hydrate form [D] of the compound of formula (II) can be characterized unambiguously by a X-Ray powder diffractogram (at 25°C and with Cu-K alpha 1 as radiation source) which displays at least the following reflections: 7.3, 12.2, 14.0, preferably at least the following reflections: 7.3, 12.2, 13.1, 13.4, 14.0, more preferably at least the following reflections: 7.3, 12.2, 13.1, 13.4, 14.0, 20.3, 22.4, most preferably at least the following reflections: 7.3, 12.2, 13.1, 13.4, 13.6, 14.0, 20.3, 21.2, 22.4, 26.3, each quoted as 2 θ value \pm 0.2°. The compound of formula (I) in the $\frac{3}{4}$ -hydrate form [D] can also be characterized unambiguously by the X-Ray powder diffractogram (at 25°C and with Cu-K alpha 1 as radiation source) as shown in Figure 4.

10 Process for the preparation of the hydrogen chloride monohydrate (III)


One aspect of the present invention is directed to a process for the preparation of a monochloride salt (II), more specific as its crystalline monohydrate form with the chemical composition as in formula (III).



15

A general advantage of the invention compared to the state of the art processes is that it delivers the compounds (I) and (III) in satisfactory yields with very low impurity levels that match the requirements for APIs in late stage clinical development or market supply. The processes according to this invention can be carried out without making use of chromatographic purification steps. Furthermore, the state of the art processes have certain drawbacks which prevent application for industrial scale production, such as process safety concerns, product decomposition and enhanced impurity formation due to increased processing times upon scale-up, and limited through-put due to high dilutions. The inventive process described in the following can be used for large scale API production in standard industrial multi-purpose equipment for chemical synthesis without disproportional need for financial and personnel resources. This is achieved by optimized throughput and avoiding impurity formation by applying optimized and simplified processes and/or tailor-made purification processes on each stage of the synthesis. In summary a total yield of 36 % was achieved with the final steps of the inventive process starting from (IV) to (III) as shown below:

30



5

Direct comparison of the state of the art processes to (I) with the final synthetic steps of the inventive process is given in the following table:

Route	Starting material	Isolated intermediates	Overall yield	chromatographic purifications	scale
Scheme 1	(IV)	4	0.8 %	4 prep. chrom. 2 RP prep. chrom.	laboratory
Scheme 2	4-aminopyrrolo[2,1-f][1,2,4]triazine-6-carbonitrile*	5	19 %	2 prep. chrom.	laboratory
Inventive Process	(IV)	3	36 %	none	industrial

*long synthetic route to example 8a via 4-aminopyrrolo[2,1-f][1,2,4]triazine-6-carbonitrile, no common intermediate between Scheme 2 and Inventive Process

10

Method 1:

According to this aspect of the present invention, the conversion of (I) to (III) as shown above is carried out by suspending or dissolving (I) in the presence of a suitable solvent, preferably in water or alcohols, more preferably in a mixture of water miscible organic solvents with water,

15

such as alcohols or ethers, most preferably ethanol or THF and treating it with hydrogen chloride or a hydrogen chloride precursor, most preferably hydrogen chloride.

5 Preference is given to initially charging the compound of the formula (I) to a solvent or solvent mixture and subsequently adding the acid, most preferably hydrogen chloride. Hydrogen chloride is added to this mixture, preferably as an aqueous solution, preferably at a temperature of between 20°C and reflux conditions, more preferably at 40°C to 60 °C, more preferably at 45 to 55°C.

10 The reaction product is isolated by filtration and washed with water miscible organic solvents, such as alcohols or ethers, preferably ethanol. The product can be dried or submitted to next process steps without drying.

15 The product is then suspended in water or low concentrated aqueous hydrogen chloride solution, preferably 0.13% hydrogen chloride in water at elevated temperature to adjust the solid state form to the desired crystalline monohydrate form with the chemical composition as in formula (III). The mixture is cooled to $20 \pm 3^\circ\text{C}$ and isolated by filtration.

20 Compound (III) is dried preferably at a temperature of 50°C and under reduced pressure, more preferably a pressure below 30 mbar without application of by-gas.

This process, referred to herein as “method 1 for preparation of compound (III),” has the advantage of transforming (I) into its monochloride, more specifically the monochloride monohydrate (III), which shows advantageous properties during application as an active pharmaceutical ingredient. Furthermore, this process has the advantage of reliably yielding the monochloride (II) as the monohydrate (III). Other forms, which may initially be formed during the salt formation step of the process, are transformed into the desired form during the treatment with dilute aqueous hydrogen chloride solution at elevated temperatures.

Method 2:

30 According to this aspect of the present invention the conversion of (I) to (III) is carried out by suspending or dissolving (I) in the presence of a suitable solvent and treating it with an acid or acid precursor. Preferably the solvent(s) are water or alcohols, more preferably a mixture of water miscible organic solvents with water, such as alcohols or ethers, most preferably ethanol or THF. The acid or acid precursor is preferably hydrogen chloride. Preference is given to
35 initially charging the compound of the formula (I) to a solvent or solvent mixture and subsequently adding the acid.

Hydrogen chloride is added to this mixture, preferably as an aqueous solution, preferably at 20°C to reflux conditions, more preferably at 40°C to 60 °C, most preferred at 45 to 55°C.

A small aliquot, preferably 1 mass% related to the initial amount of (I), of monohydrate (III) (e.g. prepared by method 1), preferably having a fine particle size by prior milling or micronisation, is added to the suspension for the purpose of seeding in order to direct the product to the desired solid state form.


The reaction mixture is cooled down and the product is isolated on a filter dryer. The filter cake is washed with a water miscible organic solvent, preferably alcohols or ethers, most preferably ethanol or a mixture of ethanol and water. Then the filter cake is washed with water or low concentrated aqueous hydrogen chloride solution, preferably 0.13% hydrogen chloride in water at 20 - 35°C.

The product is dried under reduced pressure and elevated temperature, such as 30 mbar and 50°C without application of by-gas.


This process, referred to herein as “method 2 for preparation of (III),” has the advantage of reliably forming (II) as the preferred monohydrate (III) immediately in the hydrogen chloride addition step, without manual handling of solid intermediates by performing reslurries or other unit operation to adjust to the desired solid state form. Surprisingly it was found, that the pseudopolymorphic form can be adjusted by adding seeding crystals into the suspension, after a hydrogen chloride salt of (I) has already been precipitated in other solid state forms. This seeding process has the advantage of improving filtration and drying properties on large scale compared to method 1 for preparation of (III).

25

This process has the advantage of strongly reducing the formation of impurities, such as (XV) and (XVI), which are formed during contact of (I) with acidic conditions:



(XV)



(XVI)

30


This is achieved by minimizing processing and handling times - especially on large scale - especially by avoiding additional acidic treatments to adjust the product to the desired polymorphic form. This allows for achieving impurity levels that match the requirements for APIs in late stage clinical development or market supply.

5


According to the inventive process, potential side products, in particular the compounds of the formula (XV) and (XVI) and further, can be separated very effectively from (III) because these side products or their salts do not precipitate under the conditions according to the present process and remain in the filtrate.

10

Another embodiment of the present invention is the compound of formula (III), substantially free of palladium, with palladium present in an amount up to 100 ppm, preferably up to 60 ppm, most preferably 0 – 2 ppm, and in a very high purity containing one or more pyrrolo-triazine substances structurally related to (I) each from 0 % to a maximum of 0.15 %, preferably each from 0 % to a maximum 0.06 % HPLC area% based on the amount of the compound of the formula (I). Pyrrolo-triazine substances structurally related to (I) include but are not limited to the compounds of the formula (XV), (XVI), (XVII), (XVIII) and (VI).




(XVII)



(XVIII)

20




(VI)

Preparation of the compound of the formula (I)


One aspect of the present invention relates to a process for preparing the compound of the formula (I) may be prepared by reacting the compound of the formula (VIIb), wherein R1 is halogen or other suitable leaving group), most preferably bromine, with the compound of the formula (VIIIb) wherein R2 is a suitable metalorganic substituent such as Li, MgR, Sn, and B, carboxylic acid, hydrogen, or boron derivatives, such as boron-esters, boron-amides, MIDA, preferably hydrogen or boron derivatives, most preferably boronic acid in the presence of a suitable catalyst. Substituent R2 may also comprise hydrogen in catalytic C-H activation reactions leading to the compound of the formula (I).

10



15

A mixture of (VIIb) and (VIIIb) is treated in the presence of a base such as hydroxides, (hydrogen-) carbonates, fluorides, or amines, in a suitable organic solvent or mixture with water, at elevated temperatures with a transition metal catalyst, preferably with a suitable palladium catalyst.



20

Preference is given to treating a mixture of the compounds of the formulas (VII) and (VIII) in THF and water with K₂CO₃ as a base and a catalyst at a temperature of 60°C to reflux for 30 min to 300 min.

Suitable palladium catalyst are, but are not limited to:
X-Phos precatalyst = Chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II)

and

5 Pd(dbpf)Cl₂ = [1,1'-Bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II)

and

PdCl₂(Amphos)₂ = Bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II).

This process yields a mixture of the compound of the formula (I) with by-products and remaining
10 reagents referred to as the crude reaction mixture. This crude reaction mixture can be processed by the following method:


Another aspect of the present invention is a process to obtain a solid and purified version of the compound of the formula (I). The process comprises treating the crude reaction mixture by addition
15 of an aqueous solution of a palladium-scavenging reagent, such as acetyl cysteine at a temperature from 20°C up to reflux temperature, most preferably at 60°C for 1h up to 24h. The solvent used during the reaction, such as THF, can be removed by distillation, optionally under reduced pressure. A suitable solvent, preferably a non-water miscible solvent that readily extracts traces of (XIX), most preferably MTBE or EtOAc can be added before or after the distillation. After cooling, preferably to
20 a temperature of from 0°C to 30°C, preferably 20°C, the compound is isolated by filtration. This purified compound (I) can be submitted to further purification processes.

In order to provide a highly purified version of the compound of the formula (I), it is charged into a suitable organic solvent or solvent mixtures and heated to elevated temperatures, most preferably a
25 mixture of THF and water or ethanol and water at temperatures such as 50°C to reflux. The compound of the formula (I) is isolated by filtration at a temperature above -10°C and below reflux temperature, preferentially between 0°C and 20°C.

Preference is given to charging the compound of the formula (I) in a mixture of tetrahydrofuran with
30 water in a ratio of 85 volumes tetrahydrofuran to 15 volumes of water and heating the mixture until a solution is obtained. THF is removed by distillation, preferentially under reduced pressure and ethanol is added in order to change the solvent composition to mainly comprise ethanol and water. The mixture is cooled to 15°C within and the compound of the formula (I) is isolated by filtration. This purification procedure can be repeated to further reduce impurity levels.

35 The compound is dried under reduced pressure and at elevated temperature.

Potential side products, in particular traces of palladium, benzothiophenyl side products, such as (XIX):



(XIX)


5 and one or more pyrrolo-triazine substances structurally related to (I) such as the starting compound (XII), (VI) and (XVIII) do not precipitate under the conditions according to the present process and remain in the filtrates.



10 Another embodiment of the present invention is the compound of formula (I) in a very high purity containing one or more pyrrolo-triazine substances structurally related to (I) each from 0 % to a maximum of 0.15 %, preferably each from 0 % to a maximum 0.06 % by HPLC area% based on the amount of the compound of the formula (I). Pyrrolo-triazine substances structurally related to (I) include but are not limited to the compounds of the formula (XII), (VI) and (XVIII).

15 Another embodiment of the present invention is the compound of formula (I) in a very high purity containing traces of palladium determined by appropriate trace methodology from 0 ppm to a maximum of 60 ppm, typically below 2 ppm.

Preparation of the compound of the formula (VII)

20 Another aspect of the present invention is a process for preparing the compound of the formula (VIIb), wherein R₁ can be chlorine, bromine or iodine, most preferred bromine, by reacting compounds of the formula (V) and (XIII) with paraformaldehyde in the presence of an acid to an intermediate product of the formula (VI). The product of formula (VI) is not isolated, but treated with a halogenation agent, such as a bromination, iodination, or chlorination agent. Preferably a bromination agent is used, most preferably N-Bromo Succinimide (NBS) in the same reaction vessel
 25 as a one-pot reaction. While intermediate (VI) is difficult to isolate and purify, especially using standard industrial operations on larger scale, the brominated derivative with the chemical structure (VII) crystallizes readily from the reaction mixture in good purity. Purity can be further enhanced by suspending (VII) in suitable solvent or solvent mixtures at elevated temperatures.





In a preferred embodiment of the process for preparation of the compound of the formula (VII) the compounds of the formula (V) and (XIII) are charged into a suitable solvent, preferably methanol, ethanol, iso-propanol, n-propanol, n-butanol and their mixtures with water, most preferred in MeOH.

15 A source of formaldehyde, preferably paraformaldehyde, formalin solutions, or other formaldehyde sources, most preferably paraformaldehyde, an acidic agent, preferably carboxylic acids, such as acetic acid, benzoic acid, propionic acid, trifluoro acetic acid, sulfonic acids, such as p-toluene sulfonic acid, benzene sulfonic acids, mineral acids, such as hydrogen chloride, sulfuric acid, phosphorous acid, most preferably acetic acid and heated to elevated temperature, preferably 40-100°C, most preferably to 60°C to reflux for 1h to 48h, preferably for 20-24h.

20 1 eq to 4 eq piperazin-2-one (XIII), 1 eq to 3 eq paraformaldehyde and 1 eq to 10 eq of acetic acid are deployed in the reaction. Preferably 1 eq to 2 eq piperazin-2-one (XIII), 1 eq to 1.5 eq paraformaldehyde and 3 eq to 7 eq of acetic acid are deployed in the reaction. Most preferably 1.5 eq piperazin-2-one (XIII), 1.1 eq paraformaldehyde and 6 eq of acetic acid are deployed in the reaction.

25 After conversion to (VI), an additional suitable solvent, such as protic and aprotic organic solvents and water can optionally be added with or without combination with an inorganic or organic base, such as triethyl amine, pyridine, Hünig's base, 2,6-lutidine, N-methyl imidazole, or inorganic bases,

such as sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, or potassium carbonate.

Most preferably, an aqueous solution of sodium hydroxide is added until a slightly acidic or neutral pH is reached. Surprisingly an optimum between best conversion, limited impurity formation, good stirring properties, and enhanced isolation properties by reduced fine particle formation can be achieved by applying a pH of 5.5 to 6.5 during bromination.


The bromination agent, preferably NBS or 1,3-dibromo-5,5-dimethylhydantoin (DBDMH), most preferably NBS, is added as a solid or as a solution in a suitable solvent, preferably acetonitrile. It is advantageous to add solid NBS in portions or by slow addition of a solution of NBS in acetonitrile, to reduce impurity formation.

The bromination is carried out at -20°C to 20°C, preferably at -10°C to 10°C, most preferred at -8°C to -2°C. It is advantageous to heat the reaction mixture to reflux and cool down again after the reaction is finished, to improve isolation.


In order to provide a highly purified version of the compound of the formula (VII), the reaction product is charged into a suitable organic solvent or solvent mixtures, preferably alcohols, ethers, nitriles, water and mixtures thereof, most preferably methanol, THF and mixtures of methanol and THF with water and heated to elevated temperatures such as 50°C to reflux. The compound of the formula (VII) is isolated by filtration at a temperature above -10°C and below reflux temperature, preferentially between 0°C and 20°C. The filter is finally washed with water or a mixture of a solvent, mixed with water, preferably MeOH or THF. Most preferable a mixture of MeOH and water.

In order to prepare the compound of the formula (VII), the filtered and washed product is dried, preferably at ambient temperature and optionally under reduced pressure. The compound of the formula (VII) is obtained as a hydrate containing approximately 5% of water.


Potential side products, in particular side products such as the compound of the formulas (XX), (XXI) and (VI) do not precipitate under the conditions according to the present process and remain in the filtrates.



(XX)



(XXI)




(VI)

Another embodiment of the present invention is the compound of formula (XII) in a very high purity. Side products include but are not limited to (XX), (XXI) and (VI) in amounts such as: (XX) from 0 % to 0.50 %, preferably 0 % to 0.30 %, (XXI) from 0 % to 0.70 %, preferably 0 % to 0.30 %, and (VI) from 0 % to 0.30 %, preferably 0 % to 0.20 % by HPLC area% based on the amount of the compound of the formula (VII).

Preparation of the compound of the formula (V)

Another aspect of the present invention is a process for preparing the compound of the formula (V)




10 (IV)

(V)

from the compound of the formula (IV) via the reaction intermediates of the formulas (XXII) and (XXIII),

15




by a reaction sequence of acidic cleavage of the BOC substituent, chlorination and etherification of the alcohol moiety, and cyclisation with a reagent containing formamidine with or without isolation of intermediates.

In a preferred embodiment of the process for preparing of the compound of the formula (XII), the compound of the formula (V) is charged into a solution of a suitable acid, in a suitable solvent until intermediate (XXII) is formed. The reaction mixture is then reacted with methanol or alkali methylate with or without the presence of a suitable base to form the reaction intermediate (XXIII). Then formamidine or a formamidine precursor is added and the mixture is heated to elevated temperature, preferably between 40°C and reflux, most preferably to 60 - 66°C. Conversion to (V) can be completed by adding a base preferentially as an aqueous solution.


In the process for preparing of the compound of the formula (V), the compound of the formula (VII) is charged into to a solution of 13 - 14 % HCl in dioxane at 19°C to 25°C. After completion of the

conversion to intermediate (XXII), typically about 6 h, the reaction mixture is charged into a mixture of methanol and a suitable base, such as K_3PO_4 , alkali methylates, inorganic carbonates, inorganic hydrogencarbonates, hydroxides, organic amine bases, preferably 1 eq to 2 eq K_3PO_4 or 2 eq to 3 eq of sodium methylate, most preferably 2.5 eq of sodium methylate at a temperature of 20°C to 30°C and stirred until complete conversion to the intermediate (XXIII), typically for 1h. Then formamidine or a formamidine precursor, most preferred 6 eq of formamidine acetate are added to the reaction mixture and the mixture is heated to 55°C to reflux (approx. 67°C) until complete conversion of the intermediate (XXIII), typically for 16 h to 20 h. An aqueous solution of a suitable base such as K_3PO_4 , alkali methylates, inorganic carbonates, inorganic hydrogencarbonates, hydroxides, organic amine bases, most preferred 4 eq K_3PO_4 is added and the mixture is heated to 55°C to reflux (67°C) until complete conversion to the compound of the formula (V), typically for 2 h. The organic solvents are removed by distillation, preferentially under reduced pressure, and iso-propyl acetate is added. The aqueous and the organic phases are separated, preferably at a temperature of 45°C, and the aqueous phase is extracted with iso-propyl acetate, preferably at a temperature of 45°C. The combined organic phases are concentrated by distillation, preferentially at moderate temperatures under reduced pressure. The resulting suspension is heated to 80°C until most of the product is dissolved again and slowly cooled to 0°C to 20°C. The product is isolated by filtration. In order to prepare the compound of the formula (XII) it is dried preferably at a temperature of 40°C to 60°C and optionally under reduced pressure.

The process has the general advantage of avoiding impurity formation. Specifically when the acidic solution of intermediate (XXII) is reacted with methanol without the presence of a base, then the side component of the formula (XXIV) is found in the product (V) of the process. The level of the side component of the formula (XXIV) in the product (V) is depending on the time for this process step. In a typical reaction at pilot plant scale of converting 120 kg (VII) with a time of 1h for this process step, around 11 % of (XXIV) are formed, leading to up to 7 % of this impurity in the final product. By charging the acidic solution of intermediate (XXII) into a solution of methanol with a suitable base, the formation of the side components of the formula (XXIV) and (XXV) can be strongly reduced.



(XXIV)



(XXV)

30

Furthermore this process leads to strongly reduced processing times and strongly reduced tar formation especially on industrial scale, thus avoiding increased effort for work-up, purification and isolation of (V). This is achieved by applying a limited amount of base, during the reaction of intermediate (XXII) with methanol, so that strongly basic conditions are avoided during the conversion with formamidine. Therefore, decomposition of reagents can be reduced. By adding an excess of base as an aqueous solution after reaction with formamidine, the complete conversion to (V) is triggered and residual formamidine side products thereof, are immediately removed to the aqueous phase, before excessive tar formation occurs.


According to the present process potential side products, in particular side products, such as the compound of the formulas (XXIII), (XXIV) and (XXV) do not precipitate under the conditions according to the present process and remain in the filtrates.

Another embodiment of the present invention is the compound of formula (V) in a very high purity. Side products include but are not limited to (XXIII), (XXIV) and (XXV) in amounts such as: (XXIII) from 0 % to 0.15 % and (XXIV) from 0 % to 0.15 % and (XXV) from 0 % to 0.15 % by HPLC area% based on the amount of the compound of the formula (I).

Another embodiment of the present invention is a recrystallization process for the purification of the compound of the formula (V). If (V) is not produced by the inventive process described here, (V) can be obtained in reduced quality, e.g. containing high amounts of side components and salts, and with low assay for use. In order to improve the quality of such samples, (V) can be recrystallized by dissolving it in mixtures of alcohols with aprotic solvents, preferably in a mixture of ethanol with isopropyl acetate at elevated temperatures up to reflux and slowly cooling down again. The purified compound (V) can be isolated in good yield and high purity.

Preparation of the compound of the formula (IV)


Another aspect of the present invention is a process for preparing the compound of the formula (IV)



(IV)

The reaction sequence depicted in scheme 8 outlines a preparation of the compound (IV) via the intermediates (XI), (XII) and (IX). It generally follows the synthetic sequence in analogy to WO 2007/064883 until the intermediate (VII), and the conversion of compound (VII) to (IV) is done in analogy to the process described in WO2013/087578. Compared to the state of the art processes, the inventive process delivers (IV) by improved methods and processes for the efficient and safe production on industrial scale and without chromatographic purification steps.

Scheme 8:



5

In the process for the preparation of the compound of the formula (XI), 2,5-dimethoxytetrahydrofuran (X) is reacted with tert-butyl hydrazinecarboxylate in the presence of pyridine hydrochloride in a solvent mixture of dioxane and pyridine at a temperature of $102 \pm 3^\circ\text{C}$. Under these conditions methanol formed during the reaction is removed by distillation. After complete conversion water and a non-water miscible organic solvent preferably di-*n*-butyl ether are added and the product can be isolated from this mixture. The inventive process to compound (XI) has been applied to large scale production and has the advantage of reduced formation of side components, especially on large scale, by using pyridine and pyridine hydrochloride salts as reagents.

The compound of the formula (XII) is prepared by reacting compound (XI) with chlorosulfonyl isocyanate in DMF. The crude product can be isolated by addition of the reaction mixture into an aqueous solution of an inorganic salt, such as hydroxides and carbonates, most preferably ammonium hydrogen carbonate, followed by filtration. The crude product is purified by dissolving it in a suitable organic compound, preferably methanol, and the product is precipitated by mixing the solution with water. The inventive process to compound (XII) has been applied to large scale production and has the advantage of delivering (XII) in good purity without chromatographic purification.

The compound of the formula (IX) is prepared by reacting compound (XII) with N-bromosuccinimide in a mixture of DMF and methyl tert-butyl ether. After hydrolysis of the reaction mixture, the product is extracted with methyl tetrahydrofuran and the solution of compound (IX) in methyl tetrahydrofuran is submitted to the next stage without isolation or purification. The inventive process to compound (IX) has been applied to large scale production and has the advantage simplifying the process by avoiding isolation of (IX) as a solid and telescoping it into the preparation of (IV).


30

The compound of the formula (IV) is prepared by reacting compound (IX) with metal organic reagents, preferably with methyl magnesium bromide and butyl lithium and addition to paraformaldehyde. Variations of yield and quality have been observed, in dependence to different batches of paraformaldehyde. This was overcome by treating paraformaldehyde with methyl tetrahydrofuran prior to use. The purified compound of the formula (IV) is obtained after hydrolysis and crystallization. The inventive process to compound (IV) has been applied to large scale production and has the advantage of delivering (IV) in good purity without chromatographic purification.

Preparation of the compound of formula (VIII)

This preparation is described in European Patent Application No. 15180755.9, the entire contents of which are hereby incorporated by reference. A preferred method is described in detail below:

Step 1:



15


The reaction of (XXXV) and (XXXIV) to (XXXIII) as shown above is carried out by condensation of (XXXV) with (XXXIV). This is done by adding a solution of an alkali alcoholate, such as sodium methanolate, in an alcohol, preferably methanol to a solution of dimethyl succinate at 25 - 40°C. Other succinate esters can be used in place of (XXXV), as the esters are cleaved during following steps.

The mixture is heated to reflux and a solution of thiophene-3-aldehyde is added. After complete conversion the mixture is hydrolyzed by addition of water and the product is extracted with toluene. (or other non-water miscible solvents) After removal of the solvent the crude (XXXIII) is purified by crystallization and/or reslurry from toluene (or other suitable solvents).

- This process has the advantage of high conversion related to the aldehyde by slow addition of the thiophene-3-aldehyd to the reaction mixture.
- This process has the advantage of applying reduced excess of dimethyl succinate for full conversion.
- This process has the advantage of giving a very pure and solid intermediate (XXXIII) after purification by crystallization or /reslurry, contributing to avoidance of purification on later stages by e.g. preparative chromatography.

30


Step 2:



The reaction of (XXXIII) to the carboxylic acid intermediate (XXXI) via (XXXII) as shown in Step 2 is carried out by ring-closure to the benzothiophen derivative (XXXII) under dehydrating conditions and hydrolysis of the ester moieties yielding the 7-hydroxy-1-benzothiophene-5-carboxylic acid (XXXI). This is done by heating (XXXIII) with acetic acid anhydride and sodium acetate in toluene at 70 - 75°C for 7h (other dehydrating agents: e.g. acid anhydrides (trifluoroacetic acid anhydride), methyl chloro formate; other bases than sodium acetate (potassium acetate; T & t can be varied for all process steps). The mixture is hydrolyzed by addition of water at 25 - 30°C. The organic phase is separated, washed with water, again, and the solvent is partially removed by distillation under reduced pressure. The remaining solution of (XXXII) in toluene is diluted with MeOH and water and an aqueous sodium hydroxide solution (other bases, mainly inorganic) is slowly added at temperatures below 45°C and finally heated to 50 - 55°C for 5h. The aqueous phase is separated and further diluted with water and the product is precipitated by addition of a strong protic acid such as HCl, HNO₃, sulfonic acids, CH₃COOH and H₂SO₄, preferably H₂SO₄ at 10 - 15°C till a pH of 2 - 3 is reached. The suspension is heated to 40 - 45°C and cooled to 25 - 30°C within 2h to improve filtration behavior of the product, and isolated by filtration.

- This process has the advantage of increased process safety for industrial scale by not using a large excess of acetic acid anhydride as a solvent, but a limited excess by dilution in toluene. Safe work-up is achieved by controlled release of energy during hydrolyzation of acetic acid anhydride under diluted conditions.
- This process has the advantage of giving reduced amounts of side products by using only moderate reaction temperatures during the ring closure step towards (XXXII).
- This process has the advantage of acceptable filtration times on industrial scale during isolation of (XXXI) by improving solid state properties during temperature treatment before isolation.
- This process has the advantage of yielding a well crystalizing solid product of intermediate (XXXI) with very high purity in very good yield, avoiding additional purification steps on intermediate (XXXII) or later stages of the synthesis.

Step 3:




(XXXI)

(XXX)


The reaction of (XXXI) to methyl 7-methoxy-1-benzothiophene-5-carboxylate (XXX) as shown in scheme is carried out by methylating the ester and phenol moiety. This is done by dissolving (XXXI) in a mixture of acetone and toluene (other solvents). After addition of a potassium carbonate (other bases inorganic, amines) the suspension is heated to 50 - 60°C and dimethylsulfate (other methylating agents: methyl iodide) is slowly added. After full conversion the solvent is partially distilled off at 85°C and water is added. Phases are separated and aqueous phase is additionally extracted with toluene. Combined organic phases are washed with water and the solvent is removed under reduced pressure at 60°C. The crude product is submitted to the next step.

Step 4:



(XXX)

(XXIX)



15

(XXVIII)

(XXVII)

The reaction of (XXX) to 7-methoxy-5-methyl-1-benzothiophene (XXVII) is done by reduction of the ester moiety to the methyl group yielding (XXVII). This is preferentially achieved by stepwise reduction through reducing the ester moiety of (XXX) to the alcohol (XXIX), followed by chlorination of the alcohol moiety to (XXVIII), followed by reduction to (XXVII) as shown in Step 4. This is done by dissolving the crude product (XXX) in an inert solvent such as ethers, for example dioxane Me-THF, CPME, and MTBE, aromatic & aliphatic hydrocarbons, for example benzene, toluene, xylol cyclohexane; preferably THF is used and addition of sodium-bis(2-methoxy-ethoxy)-aluminium-dihydride (Red-Al®) solution in toluene at 25 - 30°C. Other suitable reducing agents include hydrogen (with a suitable catalyst), LAH, boranes and silanes.

The mixture is hydrolyzed by addition of aqueous sodium hydroxide solution (other aqueous bases) and the product is extracted with toluene (other no-water miscible solvents or precipitated/crystallized by anti-solvent addition) and isolated by removing the solvent under reduced pressure at 60°C.

- 5 Crude (XXIX) is dissolved in toluene and at 50 - 55°C aqueous HCl is slowly added. Other chlorinated agents such as SOCl₂ may be utilized. After complete conversion the mixture is hydrolyzed with aqueous sodium bicarbonate solution. The organic phase is dried by treatment with brine, Na₂SO₄ and azeotropic drying by removing the solvent under reduced pressure at 60°C.


Also, other leaving groups can be used as an alternative chlorine in structure (XXVIII), such as Br,
10 I, F, RSO₃, for example.

Crude product (XXVIII) is dissolved in an inert solvent such as ethers, for example Dioxane Me-THF, CPME, and MTBE, aromatic & aliphatic hydrocarbons, for example benzene, toluene, xylol cyclohexane; preferably THF is used and a reduced using a reducing agent such as sodium-bis(2-methoxy-ethoxy)-aluminum-dihydride (Red-Al®) solution in toluene is added at 25 - 30°C. Other
15 suitable reducing agents include hydrogen (with a suitable catalyst), LAH, boranes and silanes.

The mixture is hydrolyzed by addition of aqueous sodium hydroxide solution (other aqueous bases) and the product is extracted with toluene (other no-water miscible solvents or precipitated/crystallized by anti-solvent addition) and isolated by removing the solvent under reduced pressure at 60°C. (XXVIII) is purified by distillation under vacuum at 125 - 160°C.

- 20 • This process has the advantage of giving 7-methoxy-5-methyl-1-benzothiophene (XXVII) in high yield and high purity without impurities according to Scheme 1 which are critical in regard of the quality of the final pharmaceutical ingredient (I) for clinical applications and cannot be easily purged in one of the following process steps towards (I).
- 25 • This process has the advantage of giving 7-methoxy-5-methyl-1-benzothiophene (XXVII), using standard multipurpose equipment and safe reagents on industrial scale. The use of drastic reaction conditions like high temperatures >160°C and unfavourable reagents like sirup-like polyphosphoric acid, which is not completely dissolved in the reaction mixture, is avoided. Very costly safety and engineering considerations on industrial scale are therefore avoided.

30 Step 5:



According to the first aspect of the present invention, the reaction of (XXVII) to benzothiophen-2-yl boronates of the formula (VIII) is done by borylation. (XXVII) is dissolved in an inert solvent such as THF and metallated by addition to a metal organic base such as *n*-butyl lithium solution in THF/hexane at -73 to -80°C. After stirring the reaction mass for 30 minutes triisopropyl borate is slowly added at -73 to -80°C. After a reaction time of 30 minutes, the mixture is hydrolyzed with aqueous potassium hydroxide solution at <10°C and phases are separated at 20 - 30°C. Aqueous phase is washed with toluene and product is precipitated by addition of aqueous sulfuric acid solution at 0 - 5°C (other acids). (XXVIII) is isolated by filtration and washed with water. The product is reslurried with a solvent such as cyclohexane at 40 - 45°C, isolated and dried at 40 - 45°C at reduced pressure.

- This process has the advantage of giving (7-methoxy-5-methyl-1-benzothiophen-2-yl)boronic acid (VIII) in high yield and high purity without impurities according to Scheme 1 which are critical in regard of the quality of the final pharmaceutical ingredient (I) for clinical applications and cannot be easily purged in one of the following process steps towards (I).

In addition to the method for preparing (VIII) from (XXVII) as described in European Patent Application No. 15180755.9, a second method for preparing (VIII) from (XXVII) is by dissolving (XXVII) in an inert solvent such as THF and metallating by addition to a metal organic base such as *n*-butyl lithium solution in THF/hexane at -55 to -80°C. After stirring the reaction mass for 30 minutes triisopropyl borate is added at -55 to -80°C. After a reaction time of 30 minutes, the mixture is warmed up to -10°C and hydrolyzed with aqueous potassium hydroxide solution at <30°C and phases are separated at 20 - 30°C. Aqueous phase is washed with toluene and the mixture is acidified by addition of aqueous sulfuric acid solution at 20°C. 2-Propanol is added and the product is crystallized by distilling of the organic solvents at elevated temperature and reduced pressure. (XXVIII) is isolated by filtration and washed with water. The product is reslurried with a solvent such as cyclohexane at 40 - 45°C, isolated and dried at 40 - 45°C at reduced pressure.

30

Definitions

Solvates in the context of the invention are designated as those forms of the compounds according to the invention which form a complex in the solid or liquid state by stoichiometric coordination with solvent molecules.

Hydrates are a specific form of solvates, in which the coordination takes place with water. Hydrates are preferred solvates in the context of the present invention.

The compounds of this invention may, either by nature of asymmetric centers or by restricted rotation, be present in the form of isomers (enantiomers, diastereomers). Any isomer may be present in which the asymmetric center is in the (*R*)-, (*S*)-, or (*R,S*)-configuration.

All isomers, whether separated, pure, partially pure, or in racemic mixture, of the compounds of this invention are encompassed within the scope of this invention. The purification of said isomers and the separation of said isomeric mixtures may be accomplished by standard techniques known in the art. For example, diastereomeric mixtures can be separated into the individual isomers by chromatographic processes or crystallization, and racemates can be separated into the respective enantiomers
5 either by chromatographic processes on chiral phases or by resolution.

In addition, all possible tautomeric forms of the compounds described above are included according to the present invention.

The present invention also encompasses all suitable isotopic variants of the compounds according to
10 the invention. An isotopic variant of a compound according to the invention is understood to mean a compound in which at least one atom within the compound according to the invention has been exchanged for another atom of the same atomic number, but with a different atomic mass than the atomic mass which usually or predominantly occurs in nature. Examples of isotopes which can be incorporated into a compound according to the invention are those of hydrogen, carbon, nitrogen,
15 oxygen, fluorine, chlorine, bromine and iodine, such as ^2H (deuterium), ^3H (tritium), ^{13}C , ^{14}C , ^{15}N , ^{17}O , ^{18}O , ^{18}F , ^{36}Cl , ^{82}Br , ^{123}I , ^{124}I , ^{129}I and ^{131}I . Particular isotopic variants of a compound according to the invention, especially those in which one or more radioactive isotopes have been incorporated, may be beneficial, for example, for the examination of the mechanism of action or of the active compound distribution in the body. Due to comparatively easy preparability and detectability,
20 especially compounds labelled with ^3H or ^{14}C isotopes are suitable for this purpose. In addition, the incorporation of isotopes, for example of deuterium, can lead to particular therapeutic benefits as a consequence of greater metabolic stability of the compound, for example an extension of the half-life in the body or a reduction in the active dose required. Such modifications of the compounds according to the invention may therefore in some cases also constitute a preferred embodiment of the
25 present invention. Isotopic variants of the compounds according to the invention can be prepared by processes known to those skilled in the art, for example by the methods described below and the methods described in the working examples, by using corresponding isotopic modifications of the particular reagents and/or starting compounds therein.

Unless otherwise noted, suitable bases for the coupling reactions, where necessary, are in particular
30 alkali carbonates, such as sodium, potassium or caesium carbonate, alkali phosphates, such as sodium or potassium phosphate, or alkali fluorides, such as potassium or caesium fluoride. Usually, these bases are employed as aqueous solutions. The reactions are carried out in organic solvents that are inert under the reaction conditions. Preferably, water-miscible organic solvents, such as 1,2-dimethoxyethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide (DMF) or
35 dimethylsulfoxide (DMSO), are employed but other inert solvents, such as dichloromethane or toluene, may also be used.

Unless otherwise noted, condensing agents suitable for the process steps, where necessary, include, for example, carbodiimides such as N,N'-diethyl-, N,N'-dipropyl-, N,N'-diisopropyl-, N,N'-dicyclohexylcarbodiimide (DCC) or N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC), phosgene derivatives such as N,N'-carbonyldiimidazole (CDI) or isobutyl chloroformate, α -chloroenamines such as 1-chloro-2-methyl-1-dimethylamino-1-propene, phosphorus compounds such as propane-phosphonic anhydride, diethyl cyanophosphonate, bis(2-oxo-3-oxazolidinyl)phosphoryl chloride, benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) or benzotriazol-1-yloxy-tris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP), and uronium compounds such as O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), 2-(2-oxo-1-(2H)-pyridyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TPTU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) or O-(1H-6-chlorobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TCTU), if appropriate in combination with further auxiliaries, such as 1-hydroxybenzotriazole (HOBt) or N-hydroxysuccinimide (HOSu), and/or bases such as alkali carbonates, for example sodium or potassium carbonate, or organic amine bases, such as triethylamine, N-methylpiperidine, N-methylmorpholine (NMM), N,N-diisopropylethylamine (DIPEA), pyridine or 4-N,N-dimethylaminopyridine (DMAP). Preference is given to using O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) or O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) in combination with N,N-diisopropylethylamine (DIPEA) and optionally 1-hydroxybenzotriazole (HOBt).

Unless otherwise noted, acceptable inert solvents for process (where necessary) are, for example, ethers such as diethyl ether, tert-butyl methyl ether (MTBE), tetrahydrofuran (THF), 1,4-dioxane or 1,2-dimethoxyethane, hydrocarbons such as benzene, toluene, xylene, hexane or cyclohexane, halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, 1,2-dichloroethane, trichloroethylene or chlorobenzene, or other solvents such as acetone, acetonitrile, ethyl acetate (EtOAC), pyridine, dimethylsulfoxide (DMSO), N,N-dimethylformamide (DMF), N,N'-dimethylpropylene urea (DMPU) or N-methylpyrrolidinone (NMP). It is also possible to use mixtures of these solvents. Preference is given to using dichloromethane, tetrahydrofuran, N,N-dimethylformamide or mixtures thereof.

30 Method for treatment:

The crystalline forms of the compound of formula (I), preferably crystalline form (III) according to the invention may have useful pharmacological properties and may be employed for the prevention and treatment of disorders in humans and animals. The forms of the compound of formula (I) according to the invention may open up a further treatment alternative and may therefore be an enrichment of pharmacy.

The crystalline forms of the compound of formula (I) according to the invention can be utilized to inhibit, block, reduce, decrease, etc., cell proliferation and/or cell division, and/or produce apoptosis.

This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of general formula (I) of the present invention, which is effective to treat the disorder. Hyperproliferative disorders include, but are not limited to, for example : psoriasis, keloids, and other hyperplasias affecting the skin, benign prostate hyperplasia (BPH), solid tumours, such as cancers of
5 the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those disorders also include lymphomas, sarcomas, and leukaemias.

Examples of breast cancers include, but are not limited to, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.

10 Examples of cancers of the respiratory tract include, but are not limited to, small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.

Examples of brain cancers include, but are not limited to, brain stem and hypophthalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumour.

15 Tumours of the male reproductive organs include, but are not limited to, prostate and testicular cancer.

Tumours of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.

20 Tumours of the digestive tract include, but are not limited to, anal, colon, colorectal, oesophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.

Tumours of the urinary tract include, but are not limited to, bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers.

Eye cancers include, but are not limited to, intraocular melanoma and retinoblastoma.

25 Examples of liver cancers include, but are not limited to, hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.

Skin cancers include, but are not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.

30 Head-and-neck cancers include, but are not limited to, laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, lip and oral cavity cancer and squamous cell.

Lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.

Sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.

Leukemias include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.

In some embodiments, the present invention further relates to a method for the treatment and/or prophylaxis of diseases, in particular the aforementioned diseases, using an effective amount of at least one of the forms of the compound of formula (I) according to the invention.

In some embodiments, the present invention further relates to a method for the treatment and/or prophylaxis of bladder cancer using an effective amount of at least one of the forms of the compound of formula (I) according to the invention.

In some embodiments, the present invention further relates to a method for the treatment and/or prophylaxis of head and neck cancer using an effective amount of at least one of the forms of the compound of formula (I) according to the invention.

In some embodiments, the present invention further relates to a method for the treatment and/or prophylaxis of lung cancer using an effective amount of at least one of the forms of the compound of formula (I) according to the invention.

The forms of the compound of formula (I) according to the invention can be used alone or in combination with other active substances if necessary. The present invention further relates to medicinal products containing at least one of the forms of the compound of formula (I) according to the invention and one or more further active substances, in particular for the treatment and/or prophylaxis of the aforementioned diseases. As suitable other active substances the following can be mentioned:

131I-chTNT, abarelix, abemaciclib, abiraterone, acalabrutinib, aclarubicin, adalimumab, adotrastuzumab emtansine, afatinib, aflibercept, aldesleukin, alectinib, alemtuzumab, alendronic acid, alitretinoin, altretamine, amifostine, aminoglutethimide, hexyl aminolevulinate, amrubicin, amsacrine, anastrozole, anecstim, anethole dithiolethione, anetumab ravtansine, angiotensin II, antithrombin III, apalutamide, aprepitant, arcitumomab, arglabin, arsenic trioxide, asparaginase, atezolizumab, avelumab, axicabtagene ciloleucel, axitinib, azacitidine, basiliximab, belotecan, bendamustine, besilesomab, belinostat, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, blinatumomab, bortezomib, bosutinib, buserelin, brentuximab vedotin, brigatinib, busulfan, cabazitaxel, cabozantinib, calcitonine, calcium folinate, calcium levofolinate, capecitabine,

capromab, carbamazepine carboplatin, carboquone, carfilzomib, carmofur, carmustine,
 catumaxomab, celecoxib, celmoleukin, ceritinib, cetuximab, chlorambucil, chlormadinone,
 chlormethine, cidofovir, cinacalcet, cisplatin, cladribine, clodronic acid, clofarabine, cobimetinib,
 5 copanlisib, crisantaspase, crizotinib, cyclophosphamide, cyproterone, cytarabine, dacarbazine,
 dactinomycin, daratumumab, darbepoetin alfa, dabrafenib, dasatinib, daunorubicin, decitabine,
 degarelix, denileukin diftitox, denosumab, depreotide, deslorelin, dianhydrogalactitol, dexrazoxane,
 dibrospidium chloride, dianhydrogalactitol, diclofenac, dinutuximab, docetaxel, dolasetron,
 doxifluridine, doxorubicin, doxorubicin + estrone, dronabinol, durvalumab, eculizumab,
 edrecolomab, elliptinium acetate, elotuzumab, eltrombopag, enasidenib, endostatin, enocitabine,
 10 enzalutamide, epirubicin, epitio stanol, epoetin alfa, epoetin beta, epoetin zeta, eptaplatin, eribulin,
 erlotinib, esomeprazole, estradiol, estramustine, ethinylestradiol, etoposide, everolimus, exemestane,
 fadrozole, fentanyl, filgrastim, fluoxymesterone, floxuridine, fludarabine, fluorouracil, flutamide,
 folinic acid, formestane, fosaprepitant, fotemustine, fulvestrant, gadobutrol, gadoteridol, gadoteric
 acid meglumine, gadoversetamide, gadoxetic acid, gallium nitrate, ganirelix, gefitinib, gemcitabine,
 15 gemtuzumab, Glucarpidase, glutoxim, GM-CSF, goserelin, granisetron, granulocyte colony
 stimulating factor, histamine dihydrochloride, histrelin, hydroxycarbamide, I-125 seeds,
 lansoprazole, ibandronic acid, ibritumomab tiuxetan, ibrutinib, idarubicin, ifosfamide, imatinib,
 imiquimod, improsulfan, indisetron, incadronic acid, ingenol mebutate, inotuzumab ozogamicin,
 interferon alfa, interferon beta, interferon gamma, iobitridol, iobenguane (123I), iomeprol,
 20 ipilimumab, irinotecan, Itraconazole, ixabepilone, ixazomib, lanreotide, lansoprazole, lapatinib,
 lasocholine, lenalidomide, lenvatinib, lenograstim, lentinan, letrozole, leuprorelin, levamisole,
 levonorgestrel, levothyroxine sodium, lisuride, lobaplatin, lomustine, lonidamine, lutetium Lu 177
 dotatate, masoprocol, medroxyprogesterone, megestrol, melarsoprol, melphalan, mepitiostane,
 mercaptopurine, mesna, methadone, methotrexate, methoxsalen, methylaminolevulinate,
 25 methylprednisolone, methyltestosterone, metirosine, midostaurin, mifamurtide, miltefosine,
 miriplatin, mitobronitol, mitoguazone, mitolactol, mitomycin, mitotane, mitoxantrone,
 mogamulizumab, molgramostim, mopidamol, morphine hydrochloride, morphine sulfate, mvasi,
 nabilone, nabiximols, nafarelin, naloxone + pentazocine, naltrexone, nartograstim, necitumumab,
 nedaplatin, nelarabine, neratinib, neridronic acid, netupitant/palonosetron, nivolumab, pentetreotide,
 30 nilotinib, nilutamide, nimorazole, nimotuzumab, nimustine, nintedanib, niraparib, nitracrine,
 nivolumab, obinutuzumab, octreotide, ofatumumab, olaparib, olaratumab, omacetaxine
 mepesuccinate, omeprazole, ondansetron, oprelvekin, orgotein, orilotimod, osimertinib, oxaliplatin,
 oxycodone, oxymetholone, ozogamicine, p53 gene therapy, paclitaxel, palbociclib, palifermin,
 palladium-103 seed, palonosetron, pamidronic acid, panitumumab, panobinostat, pantoprazole,
 35 pazopanib, pegaspargase, PEG-epoetin beta (methoxy PEG-epoetin beta), pembrolizumab,
 pegfilgrastim, peginterferon alfa-2b, pembrolizumab, pemetrexed, pentazocine, pentostatin,
 peplomycin, Perflubutane, perfosfamide, Pertuzumab, picibanil, pilocarpine, pirarubicin, pixantrone,
 plerixafor, plicamycin, poliglusam, polyestradiol phosphate, polyvinylpyrrolidone + sodium
 hyaluronate, polysaccharide-K, pomalidomide, ponatinib, porfimer sodium, pralatrexate,

prednimustine, prednisone, procarbazine, procodazole, propranolol, quinagolide, rabeprazole, racotumomab, radium-223 chloride, radotinib, raloxifene, raltitrexed, ramosetron, ramucirumab, ranimustine, rasburicase, razoxane, refametinib, regorafenib, ribociclib, risedronic acid, rhenium-186 etidronate, rituximab, rolapitant, romidepsin, romiplostim, romurtide, rucaparib, samarium-153 (153Sm) leixidronam, sargramostim, sarilumab, satumomab, secretin, siltuximab, sipuleucel-T, sizofiran, sobuzoxane, sodium glycididazole, sonidegib, sorafenib, stanozolol, streptozocin, sunitinib, talaporfin, talimogene laherparepvec, tamibarotene, tamoxifen, tapentadol, tasonermin, teceleukin, technetium (99mTc) nofetumomab merpentan, 99mTc-HYNIC-[Tyr3]-octreotide, tegafur, tegafur + gimeracil + oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, thyrotropin alfa, tioguanine, tisagenlecleucel, tocilizumab, topotecan, toremifene, tositumomab, trabectedin, trametinib, tramadol, trastuzumab, trastuzumab emtansine, treosulfan, tretinoin, trifluridine + tipiracil, trilostane, triptorelin, trametinib, trofosfamide, thrombopoietin, tryptophan, ubenimex, valatinib, valrubicin, vandetanib, vapreotide, vemurafenib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vismodegib, vorinostat, vorozole, yttrium-90 glass microspheres, zinostatin, zinostatin stimalamer, zoledronic acid, and zorubicin.

Pharmaceutical compositions:

It is possible for the crystalline form of the compound of formula (I) according to the present invention to have systemic and/or local activity. For this purpose, it can be administered in a suitable manner, such as, for example, via the oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, vaginal, dermal, transdermal, conjunctival, otic route or as an implant or stent.

For these administration routes, it is possible for the crystalline form of the compound of formula (I) according to the present invention to be administered in suitable administration forms.

For oral administration, it is possible to formulate the crystalline form of the compound of formula (I) according to the present invention to dosage forms known in the art that deliver the compounds of the invention rapidly and/or in a modified manner, such as, for example, tablets (uncoated or coated tablets, for example with enteric or controlled release coatings that dissolve with a delay or are insoluble), orally-disintegrating tablets, films/wafers, films/lyophilisates, capsules (for example hard or soft gelatine capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. It is possible to incorporate the compound according to the invention in crystalline and/or amorphised and/or dissolved form into said dosage forms.

Parenteral administration can be effected with avoidance of an absorption step (for example intravenous, intraarterial, intracardial, intraspinal or intralumbal) or with inclusion of absorption (for example intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal). Administration forms which are suitable for parenteral administration are, inter alia, preparations for

injection and infusion in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.

Examples which are suitable for other administration routes are pharmaceutical forms for inhalation [inter alia powder inhalers, nebulizers], nasal drops, nasal solutions, nasal sprays; 5 tablets/films/wafers/capsules for lingual, sublingual or buccal administration; suppositories; eye drops, eye ointments, eye baths, ocular inserts, ear drops, ear sprays, ear powders, ear-rinses, ear tampons; vaginal capsules, aqueous suspensions (lotions, mixturae agitandae), lipophilic suspensions, emulsions, ointments, creams, transdermal therapeutic systems (such as, for example, patches), milk, pastes, foams, dusting powders, implants or stents.

10 The crystalline form of the compound of formula (I) can be incorporated into the stated administration forms. This can be effected in a manner known per se by mixing with pharmaceutically suitable excipients. Pharmaceutically suitable excipients include, inter alia,

- fillers and carriers (for example cellulose, microcrystalline cellulose (such as, for example, Avicel[®]), lactose, mannitol, starch, calcium phosphate (such as, for example, Di-Cafos[®])),
- 15 • ointment bases (for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols),
- bases for suppositories (for example polyethylene glycols, cacao butter, hard fat),
- solvents (for example water, ethanol, isopropanol, glycerol, propylene glycol, medium chain-length triglycerides fatty oils, liquid polyethylene glycols, paraffins),
- 20 • surfactants, emulsifiers, dispersants or wetters (for example sodium dodecyl sulfate), lecithin, phospholipids, fatty alcohols (such as, for example, Lanette[®]), sorbitan fatty acid esters (such as, for example, Span[®]), polyoxyethylene sorbitan fatty acid esters (such as, for example, Tween[®]), polyoxyethylene fatty acid glycerides (such as, for example, Cremophor[®]), polyoxethylene fatty acid esters, polyoxyethylene fatty alcohol ethers,
- 25 • glycerol fatty acid esters, poloxamers (such as, for example, Pluronic[®]),
- buffers, acids and bases (for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine),
- isotonicity agents (for example glucose, sodium chloride),
- 30 • adsorbents (for example highly-disperse silicas),
- viscosity-increasing agents, gel formers, thickeners and/or binders (for example polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropyl-cellulose, carboxymethylcellulose-sodium, starch, carbomers, polyacrylic acids (such as, for example, Carbopol[®]); alginates, gelatine),
- 35 • disintegrants (for example modified starch, carboxymethylcellulose-sodium, sodium starch glycolate (such as, for example, Explotab[®]), cross- linked polyvinylpyrrolidone, croscarmellose-sodium (such as, for example, AcDiSol[®])),

- flow regulators, lubricants, glidants and mould release agents (for example magnesium stearate, stearic acid, talc, highly-disperse silicas (such as, for example, Aerosil[®])),
- coating materials (for example sugar, shellac) and film formers for films or diffusion membranes which dissolve rapidly or in a modified manner (for example polyvinylpyrrolidones (such as, for example, Kollidon[®]), polyvinyl alcohol, hydroxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxypropylmethylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyacrylates, polymethacrylates such as, for example, Eudragit[®])),
- capsule materials (for example gelatine, hydroxypropylmethylcellulose),
- synthetic polymers (for example polylactides, polyglycolides, polyacrylates, polymethacrylates (such as, for example, Eudragit[®]), polyvinylpyrrolidones (such as, for example, Kollidon[®]), polyvinyl alcohols, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and blockcopolymers),
- plasticizers (for example polyethylene glycols, propylene glycol, glycerol, triacetine, triacetyl citrate, dibutyl phthalate),
- penetration enhancers,
- stabilisers (for example antioxidants such as, for example, ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate),
- preservatives (for example parabens, sorbic acid, thiomersal, benzalkonium chloride, chlorhexidine acetate, sodium benzoate),
- colourants (for example inorganic pigments such as, for example, iron oxides, titanium dioxide),
- flavourings, sweeteners, flavour- and/or odour-masking agents.

The present invention furthermore relates to a pharmaceutical composition which comprise at least the crystalline form of the compound of formula (I) according to the present invention, conventionally together with one or more pharmaceutically suitable excipient(s), and to their use according to the present invention.

Dosage of the pharmaceutical compositions of the present invention:

Based upon laboratory techniques known to evaluate compounds useful for the treatment of disorders, by pharmacological assays for the determination of treatment of the conditions identified above in mammals, and by comparison of these results with the results of known medicaments that are used to treat these conditions, the effective dosage of the compound of this invention can readily be determined for treatment of each desired indication. The amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.

Of course the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age and general condition of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like. The desired mode of treatment and number of doses of a compound of the present invention or a pharmaceutically acceptable salt or ester or composition thereof can be ascertained by those skilled in the art using conventional treatment tests.

The weight data in the tests and examples which follow are, unless stated otherwise, percentages by weight; parts are parts by weight. Solvent ratios, dilution ratios and concentration data of liquid/liquid solutions are based on each case on the volume.

Examples

Abbreviations and Acronyms:

Ac	acetyl
Ac ₂ O	acetic anhydride
AcOH	acetic acid
aq.	aqueous (solution)
Boc	<i>tert</i> -butoxycarbonyl
br.	broad (¹ H-NMR signal)
Bu	butyl
cat.	catalytic
conc.	concentrated
d	doublet (¹ H-NMR signal)
DBDMH	1,3-dibromo-5,5-dimethylhydantoin
DCI	direct chemical ionization (MS)
DCM	dichloromethane
Dess-Martin periodinane	1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(<i>1H</i>)-one
DIPEA	<i>N,N</i> -diisopropylethylamine
DMF	<i>N,N</i> -dimethylformamide
DMSO	dimethylsulfoxide
EI	electron impact ionization (MS)
eq.	equivalent(s)
ESI	electro-spray ionization (MS)
Et	ethyl

EtOAc	ethyl acetate
GC-MS	gas chromatography-coupled mass spectroscopy
h	hour(s)
Hal	halogen
¹ H-NMR	proton nuclear magnetic resonance spectroscopy
HPLC	high performance liquid chromatography
iPr	isopropyl
LC-MS	liquid chromatography-coupled mass spectroscopy
Me	methyl
MeOH	methanol
min	minute(s)
MS	mass spectroscopy
m/z	mass-to-charge ratio (MS)
NBS	<i>N</i> -bromosuccinimide
<i>n</i> -Bu	<i>n</i> -butyl
NCS	<i>N</i> -chlorosuccinimide
of th.	of theory (chemical yield)
Pd/C	palladium on charcoal
PdCl ₂ (dppf)	[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
Pd(dba) ₂	bis(dibenzylideneacetone)palladium
Ph	phenyl
PPA	polyphosphoric acid
q	quartet (¹ H-NMR signal)
quant.	quantitative (yield)
rac	racemic
R _f	TLC retention factor
RP	reverse phase (HPLC)
rt	room temperature
R _t	retention time (HPLC)
s	singlet (¹ H-NMR signal)
sat.	saturated (solution)
t	triplet (¹ H-NMR signal)
TBAF	tetra- <i>n</i> -butylammonium fluoride
TBDMS	<i>tert</i> -butyldimethylsilyl
TBTU	<i>N</i> -[(1 <i>H</i> -benzotriazol-1-yl)oxy](dimethylamino)methylene]- <i>N</i> -methyl- methanaminium tetrafluoroborate
tBu	<i>tert</i> -butyl
<i>tert</i>	tertiary
TFA	trifluoroacetic acid

THF

tetrahydrofuran

TLC

thin layer chromatography

Methods:**DSC/TG**

DSC thermograms were recorded using Differential Scanning Calorimeters (model DSC7, Pyris-1 or
5 Diamond) from Perkin-Elmer. The measurements were performed with a heating rate of 20 Kmin⁻¹,
eventually 2 Kmin⁻¹ using non-gastight aluminium pans. Flow gas was nitrogen. There was no sample
preparation.

TGA thermograms were recorded using thermobalances (model TGA7 and Pyris 1) from Perkin-Elmer.
The measurements were performed with a heating rate of 10 Kmin⁻¹ using open platinum pans. Flow gas
10 was nitrogen. There was no sample preparation.

XRPD

X-Ray diffraction patterns were recorded at room temperature using XRD-diffractometers X'Pert PRO
(PANalytical) and STOE STADI-P (radiation Cu K alpha 1, wavelength 1.5406 Å). There was no
15 sample preparation. All X-Ray reflections are quoted as °2Θ (theta) values (peak maxima) with a
resolution of ±0.2°.

Raman

Raman spectra were recorded at room temperature using FT-Raman-spectrophotometers (model RFS
100 and MultiRam, Wavenumber range: 3500 - 100 cm⁻¹) from Bruker. Resolution was 2 cm⁻¹. Number
20 of scans: 64. Measurements were performed in glass vials or aluminium discs. There was no sample
preparation.

IR

IR spectra were recorded at room temperature using an IR Spectrometer Bruker Tensor 37 with HATR-
device in a wavenumber range of 4000 to 550 cm⁻¹. Resolution was 2 cm⁻¹. Number of scans: 64. There
25 was no sample preparation.

HPLC (method 1):

System: High performance liquid chromatograph equipped with gradient pumps, UV detector & attached with data recorder and integrator software; column: Waters XBridge Phenyl (150 mm*2.1 mm, 3.5 μ m); flow: 0.5 mL/min; column temperature: 25°C; detection 226 nm, run time: 30 min; mobile phase A: 385 mg CH₃COONH₄ in 1 L deionized water, pH 8.5 adjusted with NH₄OH 25 % (ca. 70 μ l); mobile phase B: acetonitrile;

Gradient:	time (min)	B (%)
	0.00	5.00
	20.00	45.0
	25.00	80.0
	30.00	80.0

HPLC (method 2):

System: High performance liquid chromatograph equipped with gradient pumps, UV detector & attached with data recorder and integrator software; column: Waters XBridge Phenyl (150 mm*2.1 mm, 3.5 μ m); flow: 0.4 mL/min; column temperature: 25°C; detection 226 nm, run time: 30 min; mobile phase A: 385 mg CH₃COONH₄ in 1 L deionized water, pH 8.5 adjusted with NH₄OH 25 % (ca. 70 μ l); mobile phase B: acetonitrile;

Gradient:	time (min)	B (%)
	0.00	5.00
	20.00	45.0
	25.00	80.0
	30.00	80.0

15

HPLC (method 3):

System: High performance liquid chromatograph equipped with gradient pumps, UV detector & attached with data recorder and integrator software; column: Waters XBridge Phenyl (150 mm*2.1 mm, 3.5 μ m); flow: 0.4 mL/min; column temperature: 25°C; detection 226 nm, run time: 30 min; mobile phase A: 770 mg CH₃COONH₄ in 0.7 L deionized water, pH 8.5 adjusted with NH₄OH 25 % (ca. 200 μ l); mobile phase B: acetonitrile;

Gradient:	time (min)	B (%)
	0.00	5.00
	20.00	45.0
	25.00	80.0
	30.00	80.0

HPLC (method 4):

System: High performance liquid chromatography system, equipped with a degasser, delay volume (dwell volume) of approx. 850 μ L, UV-VIS Detector and chromatography data system. Stationary phase: Meteoric Core C18 (150 mm length, 3.0 mm ID, 2.7 μ m particle size); mobile phase A: 1.15 g $\text{NH}_4\text{H}_2\text{PO}_4$ + 155 μ L H_3PO_4 85% / 1 L water (pH 3.0); mobile phase B: acetonitrile/ methanol 52 : 48 v/v; UV detection at 226 nm; oven temperature: 65°C, injection volume: 6 μ l; linear gradient:

Gradient:	time (min)	flow (mL/min)	A (%)	B (%)
	0	0,90	80,0	20,0
	8,5	0,90	62,0	38,0
	13,0	0,90	50,5	49,5
	21,0	1,20	30,2	69,8
	25,0	1,20	20,0	80,0
	35,0	1,20	20,0	80,0

HPLC (method 5):

System: High performance liquid chromatograph equipped with gradient pumps, UV detector & attached with data recorder and integrator software; column: Kromasil C18 (250 mm*4.6 mm, 5 μ m); flow: 0.4 mL/min; column temperature: 25°C; detection 226 nm, run time: 30 min; mobile phase A: deionized water with 0.1% H_3PO_4 , mobile phase B: acetonitrile;

Gradient:	time (min)	B (%)
	0.00	10
	20.00	90
	30.00	90
	31.00	10


15

Residual solvents (determined by GC method 1):

System: Headspace injector, gas chromatograph with splitter, autosampler, 2 flame ionisation detector (FID) and data analysis system.

20


Residual elements: ICP-MS

Example 1: tert-butyl 1H-pyrrol-1-ylcarbamate (XI)

A stirred reaction vessel was initially charged with 1045 kg of dioxane, 350 kg of tert-butyl
5 hydrazinecarboxylate and 420 kg 2,5-dimethoxytetrahydrofuran, and then 21.4 kg of
pyridine hydrochloride and 343 kg of pyridine were added. Transfer lines were rinsed with
a total amount of 40 L of dioxane. The reaction mixture was heated to $102 \pm 3^\circ\text{C}$ for 7 h and
1620 L of solvents were distilled off. The batch was cooled down to $25 \pm 5^\circ\text{C}$ and 1750 kg of
water were charged into the reactor over 1 h keeping the temperature at $22 \pm 3^\circ\text{C}$. The mixture
10 was stirred for at least 30 min, then 270 kg of di-*n*-butyl ether were added and the temperature
was adjusted to $10 \pm 3^\circ\text{C}$. The suspension was stirred for 2 h and then isolated on a centrifuge
in two portions. Each portion was washed with a mixture of 67 kg di-*n*-butyl ether and 60 kg
heptanes, followed by 175 L of heptanes. The product was dried at 60°C and 288 kg of tert-
butyl 1H-pyrrol-1-ylcarbamate (XI) were obtained in 60% of theoretical yield.

15

HPLC (method 2): purity 98.66 % ($R_t = 15.47$ min) tert-butyl 1H-pyrrol-1-ylcarbamate

Example 2: tert-butyl (2-cyano-1H-pyrrol-1-yl)carbamate (XII)

20


190 kg of tert-butyl 1H-pyrrol-1-ylcarbamate (XII) and 678 kg of anhydrous DMF were
stirred at $22 \pm 3^\circ\text{C}$ in a reaction vessel until the product was dissolved. The batch was cooled
to $0 \pm 3^\circ\text{C}$ and 163 kg of chlorosulfonyl isocyanate were slowly added over a minimum time
period of 2.5 h keeping the mixture at this temperature. The mixture was stirred for one
25 additional hour. In a second stirred reaction vessel a solution of 272 kg ammonium hydrogen
carbonate in 2660 kg of water was provided and the reaction mixture was transferred onto
this solution by maintaining a temperature below 25°C . The first reactor and the transfer line
were rinsed with 20 L of DMF followed by 20 L of water.

The mixture was kept stirring at $22 \pm 3^\circ\text{C}$ for 2 h, the crude product was isolated on a
30 centrifuge in two portions, and each portion was washed twice with 760 L of water.

The crude product was dissolved in 452 kg of methanol at $37 \pm 3^\circ\text{C}$ in a stirred reaction vessel. 1197 kg of water were provided in a second reactor at $22 \pm 3^\circ\text{C}$ and the methanolic solution in was dosed into the water within 1 h keeping the temperature at $22 \pm 3^\circ\text{C}$. The first reactor and the transfer line were rinsed with 20 L of water and the mixture was stirred
5 for 2 h. The product was isolated on a centrifuge in two portions, and each portion was washed with 143 L of a mixture of water and methanol of 4 : 1 volumes. 173 kg tert-butyl (2-cyano-1H-pyrrol-1-yl)carbamate (XII) were obtained in 80 % of theoretical yield after drying at 50°C .

10 HPLC (method 3): purity 98.7 % ($R_t = 17.28$ min) tert-butyl (2-cyano-1H-pyrrol-1-yl)carbamate

Example 3: tert-butyl (4-bromo-2-cyano-1H-pyrrol-1-yl)carbamate (IX)




15

180 kg of tert-butyl (2-cyano-1H-pyrrol-1-yl)carbamate (XII) and 508 kg of DMF were stirred in a reaction vessel and 666 kg methyl tert-butyl ether were added. The batch was cooled to $2 \pm 3^\circ\text{C}$ and 171 kg of N-bromosuccinimide were added in 15 portions within 2.5 h at this temperature.

20

The mixture was hydrolysed by addition of a solution of 13.1 kg sodium sulphite in 740 L of water within 40 - 50 min, keeping the temperature below 25°C . The batch was stirred at $22 \pm 3^\circ\text{C}$ for 30 - 60 min, and then the lower aqueous phase was discarded. The organic phase was washed twice with 360 L of water and approximately 540 L of solvent were
25 removed by distillation at $45 \pm 5^\circ\text{C}$ under reduced pressure. The residual mixture was diluted with 310 kg of methyl tetrahydrofurane and approximately 360 L of solvent were removed by distillation at $45 \pm 5^\circ\text{C}$ under reduced pressure.

310 kg of methyl tetrahydrofurane were added and 733 kg of a solution of tert-butyl (4-bromo-2-cyano-1H-pyrrol-1-yl)carbamate (IX) was obtained and converted in the next
30 chemical step without further purification.

Example 4: tert-butyl [2-cyano-4-(hydroxymethyl)-1H-pyrrol-1-yl]carbamate (IV)

The solution of tert-butyl (4-bromo-2-cyano-1H-pyrrol-1-yl)carbamate (IX) in methyl
5 tetrahydrofuran from previous stage, corresponding to conversion of 140kg of tert-butyl (2-
cyano-1H-pyrrol-1-yl)carbamate (XII), was stirred in a first reaction vessel, diluted with 950
kg of methyl tetrahydrofuran and cooled to -40 ± 3 °C. 88.6 kg of a 35 % solution of methyl
magnesium bromide in methyl tetrahydrofuran was added, keeping the temperature at -40
 ± 3 °C, followed by 10 L methyl tetrahydrofuran. The mixture was stirred for 30 min at -
10 43 ± 6 °C and then 123 kg of a solution of 23 % butyl lithium in hexane was added, keeping
the temperature at -43 ± 6 °C, followed by 10 L methyl tetrahydrofuran. The mixture was
stirred for 45 - 60 min at this temperature.

Treatment of paraformaldehyde: 81 kg of paraformaldehyde were stirred in 243 L of methyl
15 tetrahydrofuran at ambient temperature, isolated by filtration and approximately 88 kg of
solvent-wet paraformaldehyde were obtained.

A second stirred reaction vessel was charged with 546 kg of methyl tetrahydrofuran and
the solvent-wet paraformaldehyde. The temperature was adjusted to 24 ± 3 °C and the cold
20 reaction mixture from the first reaction vessel was transferred via an insulated pipe into the
paraformaldehyde slurry within 2 h keeping the batch temperature at 24 ± 3 °C. The first
reactor and the transfer line was rinsed with 40 L of methyl tetrahydrofuran and the batch
was stirred for 1.5 h at 24 ± 3 °C.

25 In a third stirred reaction vessel a solution of 193 kg ammonium chloride in 840 L of water
was prepared at 12 ± 3 °C and the reaction mixture was dosed into this solution, followed by
40 L of methyl tetrahydrofuran keeping the temperature at 12 ± 3 °C. A solution of 155 kg
citric acid in 280 L of water was added and the mixture was stirred at 12 ± 3 °C for at least
15 min. The lower aqueous layer was discarded and the organic phase was washed with 280
30 kg of 15 % aqueous sodium chloride solution. The batch was concentrated by distillation
under reduced pressure keeping the batch temperature at 45 ± 5 °C until a residual volume of
around 560 L.


The starting of the procedures was repeated for another time in analogues fashion and the two batches were combined in a stirred reaction vessel.

Total batch size now corresponds to a total amount of 280 kg tert-butyl (2-cyano-1H-pyrrol-5-yl)carbamate (XII) being converted through the sequence of bromiation and metalation and addition to paraformaldehyde.

The mixture resulting from two batches was concentrated to a residual volume of about 600 L by distillation under reduced pressure keeping the batch temperature at $45 \pm 5^\circ\text{C}$, and then 10 1400 L n-heptane were added. About 1400 L of solvent were removed by distillation under reduced pressure keeping the batch temperature at $45 \pm 5^\circ\text{C}$. The distillation was stopped and the batch was cooled to $25 \pm 5^\circ\text{C}$. Then 1400 L n-heptane were added and about 1400 L of solvent were removed by distillation under reduced pressure keeping the batch temperature at $45 \pm 5^\circ\text{C}$. 140 L of ethyl acetate were added at $50 \pm 3^\circ\text{C}$ and the batch was 15 kept at this temperature for 20 - 30 min, cooled to $2 \pm 3^\circ\text{C}$ and stirred for 1 h. The product was isolated on a centrifuge and washed twice with 140 L of a mixture of 2 volumes n-heptane and 1 volume of ethyl acetate. The product was dried at 40°C and 184 kg (57 % of theoretical yield) were obtained.

20 HPLC (method 2): purity 97.8 % ($R_t = 13.83$ min) tert-butyl [2-cyano-4-(hydroxymethyl)-1H-pyrrol-1-yl]carbamate

25 **Example 5: 6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (V)**



A stirred reaction vessel was charged with 905 kg of 13.6 % HCl in dioxane solution and the temperature was adjusted to $25 \pm 5^\circ\text{C}$. 200 kg of tert-butyl [2-cyano-4-(hydroxymethyl)-30 1H-pyrrol-1-yl]carbamate (IV) were added in 5 portions within 140 min, keeping the temperature below 30°C . The mixture was stirred for 6 h at $22 \pm 3^\circ\text{C}$. In another stirred reaction vessel a mixture of 948 kg MeOH and 380 kg of a solution of 30 % sodium methylate in methanol was provided and the reaction mixture was dosed into this solution,

keeping the temperature at 15 - 30°C. The reactor and the transfer line was rinsed with 102 kg of dioxane and the reaction mixture was stirred at 22 +/- 3°C for 1 h. 526 kg of formamidine acetate were added and the batch was heated to 63 +/- 3°C and kept at this temperature for 18.5 h.

5

A solution of 1163 kg K₃PO₄ in 2597 kg of water was added and the reaction mixture was kept at 63 +/- 3°C for 2 h.

The mixture was concentrated by distillation at a maximum internal temperature of 40°C at 10 500-100 mbar, until no more distillate was collected (approx. 2450 L of distillate). The reaction mixture was heated to 45 +/- 3°C and 1390 kg of iso-propyl acetate were added. The biphasic mixture was stirred for 30 min at this temperature, then the layers were separated and the aqueous layer was again extracted with 1390 kg of iso-propyl acetate at 15 45 +/- 3°C. The organic phases were combined and passed through a filter at 45 +/- 3°C into a stirred reaction vessel in order to remove insoluble matter.

The solution was concentrated at a maximum internal temperature of 45°C at <300 mbar to a residual volume of approximately 600 - 800 L.

20 The mixture was heated to reflux at 95°C, kept at this temperature for at least 30 min until a solution was obtained, and then slowly cooled down to 0 +/- 3°C and kept at this temperature for 4 h. Then the product was isolated by filtration. The filter cake was washed with 176 kg of iso-propyl acetate and dried in an oven at 50°C. 102.5 kg of (V) was obtained as a solid in 68 % yield.

25

HPLC (method 5): purity 99.7 % (6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine) (Rt = 4.6 min), 0.09 % (XXIV) at RRT 1.55, 0.05 % (XXV)

Assay for use: 99.0 % (against external standard)

30


Recrystallization process

A stirred reaction vessel was charged with 510 g (V) (purity by hplc: 89.7 area% and 85.2% assay for use), 1020 mL isopropyl acetate and 331 mL ethanol and heated to reflux for 1h. The mixture was cooled to 0°C within 3 h and stirred at 0°C for additional 2 h. Purified (V) 35 was isolated by filtration and washed three times with 510 mL cold isopropyl acetate. (V) was dried at 30°C at reduced pressure and 331 g (V) (66.7 % yield) were obtained

HPLC (method 1: purity 99.6 % (6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine)
Assay for use: 100.6 % (against external standard)

5

Example 7: 4-([4-amino-5-bromo-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl)piperazin-2-one (VII)



10

Method 1: pH 7.2:

A stirred reaction vessel was charged with 93.8 kg 6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (V), 78.8 kg piperazin-2-one and 726 kg methanol, heated to 22 ± 3 °C and stirred for at least 30 min at this temperature. The mixture was passed through a filter in order to remove insoluble matter and the filtrate was collected in another stirred reaction vessel. The first vessel and the filter were rinsed with 178 kg of methanol. The temperature was adjusted to 22 ± 3 °C and 188 kg acetic acid were added at this temperature, followed by 20 kg of methanol. 17.4 kg paraformaldehyde were added and the batch was heated to reflux for 24 h. The mixture was cooled down to 25 ± 5 °C and after completion of the reaction (compound (V) ≤ 6.0 % according to HPLC) the reaction mixture was neutralized to $\text{pH } 7.2 \pm 0.2$ keeping the batch temperature at 25 ± 5 °C by addition of 146 kg 50 % aqueous sodium hydroxide solution, followed by 20 kg of methanol.

The mixture was cooled to -5 ± 3 °C and 103.2 kg N-bromosuccinimide were charged into the reactor in small portions over a period of not less than 2 h keeping the batch temperature at -5 ± 3 °C. After the end of the addition, the mixture is stirred for at least 15 min, and then was heated to reflux for 1h, again cooled to 22 ± 3 °C within 2 h and hold at this temperature for an additional hour. The crude product was isolated by centrifugation, mother liqueur can be recirculated through the centrifuge to finalize isolation of all material. The isolated crude product was washed twice with 148 kg of methanol.

30

The crude reaction product was transferred into a stirred reaction vessel together with 741 kg of methanol, heated to 25 ± 5 °C and stirred for at least 10 min at this temperature. The

mixture was heated to reflux for 3 h to 3.5 h, again cooled to $10 \pm 3^\circ\text{C}$ within 3 h and hold at this temperature for an additional hour. The purified product was isolated by centrifugation and the filter cake was washed twice with 148 kg of methanol.

5 The purified product was transferred into a stirred reaction vessel together with 741 kg of methanol, heated to $25 \pm 5^\circ\text{C}$ and stirred for at least 10 min at this temperature. The mixture was heated to reflux for 3 h to 3.5 h, again cooled to $10 \pm 3^\circ\text{C}$ within 3 h and hold at this temperature for an additional hour. The pure product was isolated by centrifugation and the filter cake was washed twice with a mixture of 74 kg methanol and 94 kg water.

10

The product was dried in thin layers on trays (ca. 2.9 kg/m^2) in a tray dryer by air ventilation at ambient temperature and 94.9 kg of 4-{[4-amino-5-bromo-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl}piperazin-2-one (VII) (45 % yield) were obtained as a hydrate, containing approximately 1 mol of water per mol of (VII).

15

HPLC (method 3): purity 99.8 % (4-{[4-amino-5-bromo-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl}piperazin-2-one) (RT = 10.8 min), relevant by-products: (XXI) at RRT (relative retention time) of 1.05: 0.09 %; (XX) at RRT 1.38: 0.07 %; (VI) at RRT 0.74: not detected

20 Assay for use: 96.1 % (against external standard)

TGA: 5.0 % loss of weight

Method 2:

A stirred reaction vessel was charged with 140.0 kg 6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (V), 117.6 kg piperazin-2-one and 1106 kg methanol, and the
25 mixture was stirred for 1 h at $22 \pm 3^\circ\text{C}$. The mixture was passed through a filter in order to remove insoluble matter and the filtrate was collected in another stirred reaction vessel. The first vessel and the filter were rinsed with 266 kg of methanol. 280 kg of acetic acid were added at $22 \pm 3^\circ\text{C}$ temperature, followed by 20 L of methanol. 26 kg Paraformaldehyde were
30 added and the batch was heated to reflux for 24 h. The mixture was cooled down to $25 \pm 5^\circ\text{C}$ and after completion of the reaction (compound (V) $\leq 6.0\%$ according to hplc) the reaction mixture was neutralized to pH 6.0 ± 0.2 keeping the batch temperature at $< 25^\circ\text{C}$ by addition of 84 kg 50% aqueous sodium hydroxide solution, followed by 20 L of methanol. The mixture is stirred at $22 \pm 3^\circ\text{C}$ for at least 15 min and then cooled to $-5 \pm 3^\circ\text{C}$.

35 In a separate stirred vessel 154 kg of N-bromo succinimide were dissolved in 934 kg of acetonitrile at 20°C . The NBS solution was transferred into the reaction mixture by keeping

the temperature at $-5 \pm 3^\circ\text{C}$ (dosing time >4 h). Residues of NBS solution were flushed with 50 L of ACN. The mixture was then stirred for 30 to 40 min at this temperature and then was heated to reflux for 1h, again cooled to $22 \pm 3^\circ\text{C}$ within 1 h and hold at this temperature for an additional hour. The crude product was isolated by filtration. The filter cake was washed
5 twice with 221 kg of methanol.

The crude reaction product was transferred into a stirred reaction vessel together with 1106 kg of methanol, heated to $25 \pm 5^\circ\text{C}$ and stirred for at least 10 min at this temperature. The mixture was heated to reflux for 3 h to 3.5 h, again cooled to $10 \pm 3^\circ\text{C}$ within 3 h and
10 hold at this temperature for an additional hour. The purified product was isolated by filtration and the filter cake was washed twice with 221 kg of methanol.


The purified product was transferred into a stirred reaction vessel together with 995 kg of methanol and 140 kg of water heated to $25 \pm 5^\circ\text{C}$ and stirred for at least 10 min at this
15 temperature. The mixture was heated to reflux for 3 h to 3.5 h, cooled to $10 \pm 3^\circ\text{C}$ within 3 h and hold at this temperature for an additional hour. The pure product was isolated by filtration and the filter cake was washed twice with a mixture of 111 kg methanol and 140 kg of water.

20 The product was dried in thin layers on trays (ca. 2.9 kg/m^2) in a tray dryer by air ventilation at ambient temperature and 208 kg of 4- $\{[4\text{-amino-5-bromo-6-(methoxymethyl)pyrrolo}[2,1\text{-f}][1,2,4]\text{triazin-7-yl]methyl}\}$ piperazin-2-one (72% yield) were obtained as a hydrate, containing approximately 1 mol of water per mol of (VII).

25 HPLC (method 3): Lot 14 purity 99.5% (4- $\{[4\text{-amino-5-bromo-6-(methoxymethyl)pyrrolo}[2,1\text{-f}][1,2,4]\text{triazin-7-yl]methyl}\}$ piperazin-2-one) (RT = 11.1 min), relevant by-products: (XXI) at RRT (relative retention time) of 1.05: 0.15 %; (XX) at RRT 1.38 min: 0.16 %; (VI) at RRT 0.74: $< 0.05\%$

30 Assay for use: 95.1 % (against external standard, a hydrate contains ca. 1 mol/5 % of water)

Example 8: 4- $\{[4\text{-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo}[2,1\text{-f}][1,2,4]\text{triazin-7-yl]methyl}\}$ piperazin-2-one (I)



27.1 kg 4-([4-amino-5-bromo-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl]piperazin-2-one (VII) were placed in 425 kg THF in a stirred reaction vessel at 10°C jacket temperature. 74 kg of water, 22.1 kg of (7-methoxy-5-methyl-1-benzothiophen-2-yl)boronic acid (VIII) and 20.5 kg of potassium carbonate were added and the reaction mixture was inerted by reducing internal pressure to 200mbar and refilling to ambient pressure with argon gas. 0.47 kg [1,1'-Bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) were added and the reactor was inerted by reducing internal pressure to 200mbar and refilling to ambient pressure with argon gas. The reaction mixture was heated to reflux (approx. 64°C internal temperature) within 90 min and stirred for additional 2 h at this temperature. A solution of 24.1 kg acetyl cysteine in 274 kg water was added at 55°C to reflux temperature. The reaction mixture was stirred at this temperature for 2h, then 242 kg of ethyl acetate were added at 55°C to reflux temperature. The jacket temperature was set to 50°C

15

After stirring for 60 min, the reaction mixture was concentrated by distilling off 366 kg of solvent from the reaction mixture at 48°C to 50°C and 500 mbar. Additional 239 kg of ethyl acetate were added and the reaction mixture was concentrated by distilling off 147 kg of solvent from the reaction mixture at 46°C to 50°C and 500 mbar. After the distillation is finished, the jacket temperature was adjusted to 75°C and the mixture was stirred for 60 min. The mixture was cooled to 20°C internal temperature within 2 h and stirred for additional 2 h. The product was isolated by filtration and washed with a mixture of 196 kg ethanol and 22 kg water.

25 The product is placed in to a stirred reaction vessel in a mixture of 456 kg THF and 91 kg water and heated to 65°C until a solution was obtained. The jacket temperature was set to

50°C and the reaction mixture was concentrated by distillation at 500 to 200 mbar, until no more distillate is collected (approximately 469 kg of distillate). 238 kg of ethanol were added and the reaction mixture was concentrated by distilling off 46 kg of solvent from the reaction mixture at 140 mbar.

5

The jacket temperature was set to 80°C, the mixture was stirred for 3 h and was then cooled to 15°C internal temperature within 3 h. The mixture was stirred for 1h and the product was isolated on a centrifuge and washed with a mixture of 298 kg ethanol and 39 kg water. The product was dried at 45°C and 30 mbar and 28.3 kg of (I) were obtained.

10

This procedure was repeated for producing a second batch of (I) by converting 27.4 kg 4-CN1CCN(C1)C2=CN=C(N)C=C2C3=CC=CC=C3C4=CC=CC=C4 and 22.1 kg of (7-methoxy-5-methyl-1-benzothiophen-2-yl)boronic acid (VIII) in analogues fashion following method 1 and 28.5 kg of (I) were obtained.

15

Purification:

28.3 kg of (I) from the first batch of (I) were placed in a stirred reaction vessel in a mixture of 413 kg THF and 81 kg water and heated to reflux at 65°C until a solution was obtained. Then the jacket temperature was set to 60°C and the mixture was passed through a heated particle filter (60°C) into another stirred reaction vessel.

20

28.5 kg of (I) from the second batch of (I) were placed in a stirred reaction vessel in a mixture of 410 kg THF and 81 kg water and heated to reflux at 65°C until a solution was obtained. Then the jacket temperature was set to 60°C and the mixture was passed through a heated particle filter (60°C) into the stirred reaction vessel already containing the first portion of the solution of (I).

25

The jacket temperature was set to 50°C and the reaction mixture was concentrated by distillation at 200 mbar, until no more distillate was collected (approximately 798 kg of distillate). 429 kg of ethanol were added and the reaction mixture was concentrated by distilling off 90 kg of solvent from the reaction mixture at 140 mbar.

30

The jacket temperature was set to 85°C, the mixture was stirred for 90 min and was then cooled to 15°C internal temperature within 3 h. The mixture was stirred for 1h and the product was isolated on a filter dryer and washed with a mixture of 354 kg ethanol and 45

35

kg water. Finally the product was dried at 45 °C and 30 mbar, yielding 53.6 kg of (I) in 78% of theoretical yield.

HPLC (method 4):

5 purity: 99.8 % (Rt = 11.6 min.), relevant by-products: (VI) at RRT (relative retention time) of 0.16: n.d.; (XVIII) at RRT 1.02 min: 0.09 %; (XV) at RRT 0.77: n.d. (XVI) at RRT 0.98: n.d.


Assay for use: 97.8 % (against external standard)

10

Residual solvents (determined by GC method 1): 0.4 % tetrahydrofuran

Residual elements (determined by ICP-MS): 0.9 mg/kg palladium

15 **Example 9: 4-{{4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl}methyl}piperazin-2-one hydrochloride hydrate (III) monohydrate [A]**



20 **Method 1:**

16.1 kg of 4-{{4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl}methyl}piperazin-2-one (I) were suspended in a mixture of 106 kg ethanol and 13 kg water by stirring in a reaction vessel. The mixture was heated to 50 ± 5°C and stirred for 1h. 5.4 ± 0.2 kg of a solution of 25 % HCl in water was added, followed by 10 kg of ethanol and the batch was stirred for 1 h at this temperature. The mixture is cooled to 0 ± 3°C within 2.5 h and stirred at 0 ± 3°C for 1 h. The product is

25

isolated by filtration and the filter is washed with 48 kg ethanol via the cold reaction vessel.
The crude product is further processed without drying.

The process is carried out four times, thus converting a total of 64.4 kg. The four crude
5 products were combined in the next process step.

2.5 kg 10 % aqueous HCl solution were diluted by 193 kg of water in a stirred reaction vessel
and the 4 crude products were suspended in this mixture. The batch was heated to $75 \pm 3^\circ\text{C}$,
stirred at this temperature for 1 h and then cooled to $20 \pm 3^\circ\text{C}$ within 3 h. The product is
10 isolated on a filter dryer and residual product is rinsed from the reaction vessel into the filter
by circulating the filtrate via the reaction vessel. The product is dried at 30 mbar and 50°C
jacket temperature and 63.7 kg (89% yield) of 4-{{[4-amino-6-(methoxymethyl)-5-(7-
methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-
yl]methyl}piperazin-2-one hydrochloride hydrate (III) are obtained in the desired
15 monohydrate [A] solid state form.

HPLC (method 4):

purity: 99.7 % (Rt = 11.9 min.), relevant by-products: (VI) at RRT (relative retention time)
of 0.16: n.d. (XVIII) at RRT 1.02 min: n.d.; (XV) at RRT 0.77: 0.07 %; (XVI) at RRT 0.98:
20 0.16 %

Assay for use: 98.2 % (against external standard, based on monochloride, monohydrate)

Residual solvents (determined by GC method 1): 0.3 % ethanol

25 Residual elements (determined by ICP-MS): 1 mg/kg palladium

Water content (Karl Fischer coulometric): 3.5 %

Ion chromatography: 6.4 % chloride

30 Method 2:

51.1 kg of 4-{{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-
yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl}piperazin-2-one (I) are suspended in a mixture
of 336 kg ethanol and 41 kg water in a stirred reaction vessel. The mixture is heated to 50°C
and 17.3 kg of a solution of 25 % HCl in water, followed by 32 kg of ethanol is added.
35 0.48kg 4-{{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-
yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl}piperazin-2-one hydrochloride hydrate (III) in
the form of monohydrate [A] are added as seed crystals (e.g. prepared according to method

1 or method 2 and additionally milled by jet mill to below 20 µm particle size) and the reaction mixture is stirred for 1 h at 50°C.

The mixture is cooled to 0°C within 2.5 h and stirred at 0°C for 1 h. The product is isolated by filtration on a filter dryer and the filter is washed with 107 kg of cold ethanol. Then the
5 filtration is stopped.

A mixture of 2.0 kg of a solution of 10% HCl in water is diluted with 154 kg of water and heated to 30°C in the stirred reaction vessel and piped into the filter dryer. The filter cake is suspended on the filter dryer at 32°C for 60 min by stirring and then filtrated.

10 The product is dried at 50°C jacket temperature and 30 mbar until a product temperature of 45°C is achieved. Then drying is continued for 2 h. 54.0 kg (95% yield) of 4-{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl}piperazin-2-one hydrochloride hydrate (III) are obtained in the desired monohydrate [A] solid state form.

15

HPLC (method 4):

purity: 99.9 % (Rt = 11.6 min.), relevant by-products: (VI) at RRT (relative retention time) of 0.16: n.d. (XVIII) at RRT 1.02 min: n.d.; (XV) at RRT 0.77: 0.04 %; (XVI) at RRT 0.98: n.d.

20 Assay for use: 98.2 % (against external standard, based on monochloride, monohydrate)

Residual solvents (determined by GC method 1): 0.2 % ethanol

Residual elements (determined by ICP-MS): 0.6 mg/kg palladium

Water content (Karl Fischer coloumetric): 3.8 %

25 Ion chromatography: 6.8 % chloride

Example 10: Processes for preparing different solid state form samples for characterization on laboratory scale:

Preparation of Monohydrate (A)

30 Crystalline form (III) as the monohydrate [A] of the compound of formula (I) was prepared as described above (according to Method 1, example 9)

Preparation of Dihydrate (B)

1 g Monohydrate form [A] of the compound of formula (II) (water content of 3.1 %) was suspended in 10 mL methanol and stirred at 0°C for five weeks. Subsequently the suspension was filtrated and the

residue was stored at room temperature until the solvent had evaporated. It transformed into the Monohydrate in the course of two weeks.

Preparation of Trihydrate (C)

1 g Monohydrate form [A] of the compound of formula (II) (water content of 3.5 %) was dissolved in
5 100 mL methanol under reflux. The solution was filtrated and stored in the refrigerator until the solvent had evaporated

Preparation of $\frac{3}{4}$ -hydrate (D)

3.5 g Monohydrate form [A] of the compound of formula (II) (water content of 3.1 %) was suspended
in 35 mL methanol and stirred at 0°C for one week. Subsequently the suspension was filtrated and the
10 residue was stored at room temperature until the solvent had evaporated

Preparation of amorphous material (E)

Monohydrate form [A] of the compound of formula (II) (water content of 3.1 %) was spray dried with ethanol/water (1 : 1).


Physical characterization of hydrate forms of the compound of formula (II)

XRPD

Reflections (Peak maxima) [2 Theta]				
Monohydrate (A)	Dihydrate (B)	Trihydrate (C)	¾-Hydrate (D)	
<u>6,9</u>	6,2	6,6	6,1	
<u>9,3</u>	<u>6,7</u>	<u>6,8</u>	<u>6,7</u>	
10,3	7,3	7,6	6,9	
<u>10,6</u>	9,4	8,8	<u>7,3</u>	
<u>11,4</u>	<u>11,7</u>	<u>11,2</u>	8,6	
12,0	<u>12,6</u>	11,6	9,8	
<u>13,3</u>	13,2	11,7	10,3	
13,7	<u>13,5</u>	<u>12,9</u>	11,4	
16,0	<u>13,9</u>	13,1	<u>12,2</u>	
16,3	14,3	<u>13,5</u>	12,6	
17,7	<u>14,5</u>	14,1	<u>13,1</u>	
18,0	15,0	14,3	<u>13,4</u>	
18,5	15,4	<u>14,6</u>	13,6	
<u>18,8</u>	16,2	14,9	<u>14,0</u>	
19,4	16,3	15,2	14,7	
20,0	16,4	15,3	15,1	
<u>20,7</u>	17,0	15,9	15,9	
21,2	17,9	17,1	16,4	
21,5	18,4	17,6	16,8	
22,0	18,7	18,2	17,0	
22,3	19,0	18,7	17,4	
22,5	19,4	19,1	17,9	
22,9	20,3	19,6	18,3	
<u>23,3</u>	21,0	20,0	18,8	
23,7	21,4	20,3	19,1	
<u>24,1</u>	21,5	21,3	19,5	
<u>24,6</u>	21,9	21,7	19,9	
25,1	22,2	22,2	<u>20,3</u>	
<u>26,0</u>	22,5	<u>22,5</u>	21,2	
26,4	23,1	23,3	<u>22,4</u>	
26,5	23,3	23,6	22,7	
26,7	23,5	24,4	23,8	


Reflections (Peak maxima) [2 Theta]			
Monohydrate (A)	Dihydrate (B)	Trihydrate (C)	³ / ₄ -Hydrate (D)
26,8	24,1	24,6	24,1
27,0	24,3	24,9	24,3
27,7	25,6	25,7	24,5
28,3	<u>25,9</u>	25,9	25,2
28,5	26,1	26,2	25,5
<u>28,9</u>	26,7	<u>26,5</u>	25,8
29,8	27,0	<u>26,5</u>	26,1
30,1	27,1	26,9	<u>26,3</u>
30,1	27,2	27,2	26,7
30,5	27,6	27,8	27,0
31,2	28,3	28,0	27,3
31,7	28,7	28,5	27,9
32,2	29,1	29,1	28,2
33,2	29,4	29,5	28,8
33,6	30,0	29,8	29,4
33,8	30,6	30,0	30,4
34,2	30,7	30,6	30,7
34,7	31,4	30,9	31,4
35,4	31,9	31,5	31,8
36,4	32,3	32,1	32,4
37,5	32,5	32,7	34,6
	32,8	33,2	35,3
	33,4	34,8	36,6
	34,4	35,9	
	35,0	36,9	
	35,8		
	36,1		
	37,1		
	38,1		
	38,5		

Crystalline form [A]: Monohydrate




5


Crystalline form [D] : 3/4-Hydrate



10 Crystalline form [C]: Trihydrate



Crystalline form [E]: Amorphous compound



Additional data on preparation and characterization of hydrate forms of (II)

Preparation of hydrate forms of 4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-
 5 benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazin-2-one-mono-
 hydrochloride compound of formula (II)

Suspensions of monohydrate (A) were prepared in various solvents and stirred at 0°C and 25°C. The residues were filtered off and dried at room temperature and ambient humidity. Table 1 summarizes the results. Reproducible preparation was not possible for all solid state forms..

10 **Table 1: Slurry experiments**

Solvent	Temperature [°C]	Stirring time [weeks]	Modification residue
Isopropanol	0	1	Monohydrate (A)
Methanol	0	2	¾-Hydrate (D)
Methanol	0	5	Dihydrate (B)
Toluene	25	4	Monohydrate (A)
Tetrahydrofuran/water (1 : 1)	25	4	Monohydrate (A)
Acetonitrile/water (1 : 1)	25	1	Monohydrate (A)
Isopropanol	25	4	Monohydrate (A)
Ethanol	25	4	Monohydrate (A)
Ethanol/water (1 : 1)	25	1	Monohydrate (A)
Methanol	25	1	Monohydrate (A)

1,4-Dioxane	25	1	Monohydrate (A)
-------------	----	---	-----------------

- Properties of hydrate forms of 4-{{4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl}piperazin-2-one-mono-
- 5 hydrochloride compound of formula (II)

Storage

The Monohydrate, $\frac{3}{4}$ -Hydrate, the Trihydrate and the Amorphous form were stored in closed vessels at 25°C and 50°C (humidity not set). The results are summarized in Table 2.

10 **Table 2: Storage at 25°C and 50°C**

Modification	Time [months]	Modification / after storage in closed vessels at	
		25°C	50°C
Monohydrate	12	Monohydrate	Monohydrate
$\frac{3}{4}$ -Hydrate	12	$\frac{3}{4}$ -Hydrate	$\frac{3}{4}$ -Hydrate
Trihydrate	12	Trihydrate	Amorphous + Trihydrate
Amorphous form	6	Amorphous form	Amorphous form

Moisture sorption

- The Monohydrate, $\frac{3}{4}$ -Hydrate, the Trihydrate and the Amorphous form were stored at various
- 15 humidities. Their moisture content was then determined by thermogravimetric analysis. The results are summarized in Table 3.

Table 3

Modification	Time months	Mass loss [%] and modification after storage at 25°C and		
		15 % r. h.	85 % r. h.	97 % r. h.

Monohydrate	12	3.7	3.7	3.7
		Monohydrate	Monohydrate	Monohydrate
$\frac{3}{4}$ -Hydrate	12	2.6	4.1	7.9
		$\frac{3}{4}$ -Hydrate	Monohydrate*	Monohydrate*
Trihydrate	12	-	3.3	6.0
			Monohydrate*	Monohydrate*
Amorphous form	6	-	4.3	5.4
			Monohydrate*	Monohydrate*

* Transition into the Monohydrate already took place during one-month-storage.

Pharmaceutical composition containing compound (III) (600 mg)

Table 4: Composition of 200 mg (API) tablets

Composition	Amount [mg]
Drug substance	
Compound (III) ^a	223.4
Excipients	
Tablet core	
Cellulose microcrystalline	139.1
Copovidone	12.2
Crospovidone	51.0
Lactose monohydrate	244.1
Magnesium stearate	6.8
Purified water ^b	q.s. ^b
Silicia, colloidal, anhydrous	3.4
Weight (uncoated tablet)	680.0
Film-coating	
Ferric oxide red ^c	1.85
Hypromellose 15 cP ^c	7.92
Macrogol ^c	2.64
Titanium dioxide ^c	0.79
Purified water ^b	q.s. ^b
Weight (film-coating)^d	13.2
Weight (coated tablet)	693.2

Table 4: Composition of 200 mg (API) tablets

	Composition	Amount [mg]
a	(III) is the hydrochloride monohydrate of the free base (I), the dose strength 200 mg is corresponding to the amount of the free base. The drug substance is used in micronized form	
b	q.s. = quantum sufficit (a sufficient quantity). Purified water is used as processing agent and quantitatively removed by the manufacturing process, except for low level of residual moisture. It does not contribute to the sum of mass of the drug product	
c	Excipients may be used as a ready-to-use mixture	
d	Theoretical amount	

Description of the Tablet Manufacturing Process

Dry Blending

5 Cellulose microcrystalline, compound (III), lactose monohydrate and crospovidone were weighted in the proportions according to Table 1 into a suitable container and blended.

Wet Granulation

After blending the mixture was granulated with the binder solution (copovidone in purified water) in a high shear granulator. After granulation, the granulate was wet sieved.

10

Drying and Dry Milling

The sieved granules were transferred to the fluid bed dryer and dried until a LOD of 3 – 4 % is reached.

After drying the granules were passed through a 0.9 mm sieve.

15

Final Blending

Cellulose microcrystalline, crospovidone and silica, colloidal, anhydrous were added to the final blend and mixed in the bin blender.

At last magnesium stearate was added to final blend and mixed.

20

Tablet Compression

The mixture was compressed on a rotary press into tablets with weight of 680.0 mg.

Coating

25 The tablets were coated into the drum coater with the coating suspension (hypromellose, macrogol, ferric oxide red, titanium dioxide in purified water).

Properties of pharmaceutical compositions containing compound (III)**Methods:**

Tablets were assessed according to the following methods:

Appearance

Appearance of tablets were assessed on a white background at daylight.

Length and width were measured.

Identity (retention time)

Identity was analyzed within the determination of assay. The retention time of compound I peak in the sample must comply with the retention time of the reference standard in reference assay within a range of $\pm 5.0\%$.

Sequence for determination of identity

Solution	Inj.
Blank	1
Reference assay	1
Sample	1

Identity (UV-spectrum)

The identity was analyzed with the determination of assay. The spectrum of the major peak in the chromatogram of the test solution should correspond to that of the major peak in the chromatogram of the compound I reference standard.

Content Uniformity

HPLC conditions

Apparatus

Agilent HPLC 1100 or equivalent

Column

Agilent Zorbax Eclipse Plus C18 · 3.5 μm ,
100 mm · 4.6 mm

Injection volume

2 μL

Injection with needle wash

Autosampler temperature

room temperature

Run time

8 min

Wavelength	226 nm
Eluent	60 % phosphate buffer 40 % acetonitrile
Flow	0.5 mL/min
Column temperature	45 °C
Vials	amber glass
Reagents and solutions	
Phosphate buffer	Weigh 1.15 g ammonium dihydrogen phosphate into a 1000 mL volumetric flask. Add 0.68 mL phosphoric acid (ultra-pure, conc.) and fill up to mark with water. Check pH and adjust to 2.40 – 2.50 with phosphoric acid or prepare new. Preparation of differing volumes is also possible. Amounts of buffering agent, phosphoric acid, and water then need to be adjusted appropriately.
Diluent	Mix water and acetonitrile in exactly equal volume shares.
Blank solution (blank)	Filter diluent through a 0.2 µm PTFE filter and discard the first few milliliters.
SST	Use reference solution.
Reference solution (reference)	Prepare solution of compound III reference substance in diluent using amber glass volumetric flask. Final concentration of compound I should be 0.1 mg/mL. Sonicate until dissolved. Stable for 14 days stored at room temperature and daylight.
Sample solution 1	Analysis will be performed with 10 single units. Weigh and transfer one tablet into a 100 mL amber volumetric flask. Add 70 mL diluent and sonicate to suspend. Cool down to room temperature, fill up to mark with diluent and mix well. Filter through a 0.2 µm PTFE filter and discard the first few milliliters. Preparation time should be less than 120 minutes
Sample solution 2 (sample)	Dilute sample solution 1 to theoretical concentration of 0.1 mg/mL of compound I with diluent. Use amber flask. Stable for 7 days stored at room temperature and daylight.

Sequence

Solution	Inj.
Blank	1
SST	6
Reference	2
Sample 1-10	1
Reference	2

Calculation:

$$cc. [\%] = \frac{\text{weight reference [mg]} \cdot P [\%] \cdot 100 \%}{100 \% \cdot \text{sample dosage per tablet [200 mg]}} \cdot f_d$$

P = Purity of reference substance

f_d = dilution factor

sample [%] =

$$\frac{\text{area sample} \cdot cc.}{\text{area reference}}$$

cc. = Calibration concentration

Acceptance criteria:

Blank	No interfering peaks at the retention time of compound I.
SST	Symmetry factor (Ph. Eur.) is between 0.8 and 1.5 RSD peak area (n=6) \leq 2.0 %
Reference (within bracketing)	RSD peak area (n=4) \leq 2.0 %
Acceptance value (USP <905> / Ph. Eur. 2.9.40)	The uniformity of dosage units of the tablets must meet the requirement of the cited quality specification. If the acceptance value (AV) of the 10 tablets is $>$ 15.0 %, test additional 20 tablets and calculate the acceptance value of 30 tablets.
Reporting:	AV If stage 2 than also: Min, Max

Degradation products

	Impurities are analyzed within the determination of assay. Degradation products can be quantified in the sample solutions for up to 7 days
Integration	SST1 has to be reported with an own process method for calculation to calculate the resolution (compound I to RRT 0.96 and RRT 1.08) with the integration parameter valley to valley. The peak RRT 0.96 (NK5) to compound I in all other chromatograms has to be integrated by drop down and the peak with a RRT 1.08 (NK11) to compound I has to be integrated by tangential skim.

Dissolution

Dissolution conditions

Apparatus	Paddle
Dissolution medium	900 mL hydrochloric acid pH 2.0 For 6 L: Dilute 6 mL hydrochloric acid (32%) with 5994 mL purified water. Adjust to pH 2 if necessary.
Stirring speed	50 rpm \pm 2 rpm

Temperature	37.0 °C ± 0.5 °C
Sample withdrawal	10 mL each after 5, 10, 15, 30, and 45 min (infinity)
Infinity test	after 30 min withdrawal adjust the stirring speed to 200 rpm
HPLC conditions	
Apparatus	Agilent HPLC 1100 or equivalent
Column	Agilent Zorbax Eclipse Plus C18 · 3.5µm, 100 mm · 4.6 mm
Injection volume	2 µL Injection with needle wash (1x)
Autosampler temperature	room temperature
Run time	8 min
Wavelength	226 nm
Eluent	60 % phosphate buffer pH 2.4 40 % acetonitrile
Flow	0.5 mL/min

Column temperature	45 °C
Vials	amber glass
Reagents and solutions	
Phosphate buffer pH 2.4	<p>For 1 L: Weigh 1.15 g ammonium dihydrogen phosphate into a 1000 mL volumetric flask. Add 0.68 mL phosphoric acid (ultra-pure, conc.) and fill up to mark with water. Check pH and adjust to 2.4 (2.35 – 2.50) with phosphoric acid or prepare new.</p> <p>For preparation of differing volumes, adjust amounts of buffering agent, phosphoric acid, and water appropriately.</p>
Diluent	Mix water and acetonitrile in exactly equal volume shares.
Blank solution (blank)	Pipette 2.0 mL diluent into a 20 mL amber volumetric flask and fill up to mark with dissolution medium. Filter through a 0.45 µm RC filter and discard the first few milliliters.
SST	Use reference solution 2.
Reference solution 1	<p>Prepare solution of compound III reference substance in diluent using amber glass volumetric flask. Final concentration of compound I should be 2.20 mg/mL. Sonicate until dissolved.</p> <p>Stable for 14 days if stored in refrigerator at 2 °C – 8 °C</p>
Reference solution 2 (reference)	<p>Dilute reference solution 1 to theoretical concentration of 0.22 mg/mL of compound I with dissolution medium. Use amber flask</p> <p>Stable for 14 days. Store in refrigerator at 2 °C – 8 °C</p>

Sample solution (sample)

Weigh 1 tablet and transfer it to one vessel. Repeat this procedure for 6 vessels. Withdraw a sample of 10 mL after the appropriate time point and filter through a 0.45 µm RC filter. Discard the first 6 mL and analyze. No medium is replaced. Use one syringe and one filter for each sampling time point.

Stable for 3 days, stored at room temperature and daylight.

Sequence

Solution	Inj.
Blank	1
SST	6
Reference	2
Sample 1-30	1
Reference	2

Calculation

Reference: cc. [mg/mL] =

$$\frac{\text{weight reference [mg]} \cdot P [\%]}{100\%} \cdot f_d$$

P = Purity of reference substance

f_d = dilution factor

sample [mg/mL] =

$$\frac{\text{area sample} \cdot \text{cc.}}{\text{area reference}}$$

Calculation of concentration in % is automatically performed by the chromatography software.

cc. = Calibration concentration

Acceptance criteria	
Blank	No interfering peaks at the retention time of compound I
SST	Symmetry factor (Ph. Eur.) is between 0.8 and 1.5 RSD area (n=6) \leq 2.0 % (cf. Fehler! Verweisquelle konnte nicht gefunden werden.)
Reference (within bracketing)	RSD area (n=4) \leq 2.0 % (cf. Fehler! Verweisquelle konnte nicht gefunden werden.)
Reporting (specified after 30 min)	Average, Min, Max, Evaluation

Table 5: Coated tablet 200 mg, packaged in HDPE-bottles

Test Acceptance criterion	Storage time [months]	25 °C/60 % RH	30 °C/75 % RH	40 °C/75 % RH
Crystalline form (III)	Initial	confirmed	-	confirmed
	1	confirmed	-	confirmed
	3	-	-	confirmed
	6	confirmed	-	confirmed
	9	-	-	-
	12	confirmed	-	-
	18	-	-	-
	24	confirmed	-	-
	36	confirmed	-	-
	48	confirmed	-	-
	60			

5

Tablets with compound III were manufactured according to the method described above and an initial XRPD was recorded. The XRPD pattern remained unchanged at all storage condition investigated over a period of 48 months.

10

Table 6: Stability in brown glass bottle

Test item	Storage time (months)	25 °C/60 % r.h.	40 °C/75 % r.h.
Material and colour	initial	slightly grey-tinged solid	
	3	slightly grey-tinged solid	slightly grey-tinged solid
	6	slightly grey-tinged solid	slightly grey-tinged solid
	9	slightly grey-tinged solid	n.t.
	12	slightly grey-tinged solid	n.t.
	18	slightly grey-tinged solid	n.t.
	24	slightly grey-tinged solid	n.t.
Water [%]	initial	3.5	
	3	3.9	3.6
	6	3.5	3.4
	9	3.5	n.t.
	12	3.6	n.t.
	18	3.6	n.t.
	24	3.5	n.t.
Ethanol [%]	initial	0.533	
	3	0.460	0.406
	6	0.467	0.435
	9	0.444	n.t.
	12	0.441	n.t.
	18	0.434	n.t.
	24	0.415	n.t.
Sum of all organic impurities [%]	initial	1.03	
	3	1.08	1.17
	6	1.05	1.00
	9	1.14	n.t.
	12	1.22	n.t.
	18	1.17	n.t.
	24	1.14	n.t.
Assay calc. on dried substance [%]	initial	100.3	
	3	99.8	98.4
	6	100.0	99.7
	9	100.0	n.t.
	12	98.1	n.t.
	18	100.4	n.t.
	24	98.8	n.t.

Table 7: Stability of tablet**200 mg strength, HDPE-bottles, concomitant study**

Test Acceptance criterion	Storage time [months]	25 °C/60 % RH	30 °C/75 % RH	40 °C/75 % RH
Appearance (formulation, form, color)	Initial	no change	no change	no change
	1	no change	no change	no change
dark red, oblong, coated tablet	3	no change	no change	no change
	6	no change	no change	no change
	9	no change	no change	-
	12	no change	no change	-
	18	no change	no change	-

200 mg strength, HDPE-bottles, concomitant study

Test	Storage time	25 °C/60 % RH	30 °C/75 % RH	40 °C/75 % RH
Acceptance criterion	[months]			
	24	no change	no change	-
	36	no change	no change	-
	48	no change	no change	-
	60			
Dissolution	Initial	81	81	81
after 30 minutes	1	82	81	80
Mean %	3	80	78	83
	6	78	76	74 / 97 ^{a, b}
Q=75 %	9 ^a	99	100	-
	12	95	97	-
	18	95	95	-
	24	102	100	-
	36	95	92	-
	48	96	96	-
	60			
Water	Initial	3.9	3.9	3.9
[%]	1	4.1	4.5	4.0
	3	3.9	4.0	4.2
≤ 8 %	6	4.5	4.9	4.8
	9	4.7	4.7	-
	12	4.6	4.3	-
	18	5.1	5.5	-
	24	4.2	4.5	-
	36	4.4	4.9	-
	48	4.7	5.3	-
	60			

200 mg strength, HDPE-bottles, concomitant study

Test	Storage time	25 °C/60 % RH	30 °C/75 % RH	40 °C/75 % RH
Acceptance criterion	[months]			
Degradation products				
Any unspecified degradation product	Initial	< 0.05	< 0.05	< 0.05
	1	< 0.05	< 0.05	< 0.05
	3	0.06	0.06	0.06
	6	0.05	0.05	0.05
	9	0.05	0.05	-
	12	0.05	0.05	-
	18	< 0.05	< 0.05	-
	24	< 0.05	0.05	-
	36	0.05	0.06	-
	48	0.06	0.05	-
60 ^c				
Sum of all degradation products	Initial	< 0.05	< 0.05	< 0.05
	1	< 0.05	< 0.05	< 0.05
	3	0.06	0.06	0.11
	6	0.05	0.05	0.05
	9	0.05	0.05	-
	12	0.05	0.05	-
	18	< 0.05	< 0.05	-
	24	< 0.05	0.05	-
	36	0.05	0.06	-
	48	0.06	0.05	-
60 ^c				
Assay	Initial	203.8	203.8	203.8
	1	208.3	206.2	205.4
	3	201.4	200.8	200.0
	6	201.1	204.9	201.6
	9	201.2	201.6	-
	12	200.3	202.9	-
	18	203.0	206.7	-
	24	202.9	200.3	-
	36	201.3	201.9	-
	48	198.2	205.8	-
60				

a Effective date of dissolution method change

b Dissolution tested after 7 months

c First application of updated evaluation method for degradation products

Figures:

Figure 1: X-Ray powder diffractogram of the Monohydrate (A) according to Example 10.

5 Figure 2: X-Ray powder diffractogram of the Dihydrate (B) according to Example 10.


Figure 3: X-Ray powder diffractogram of the Trihydrate (B) according to Example 10.

Figure 4: X-Ray powder diffractogram of the 3/4-hydrate (D) according to Example 10.


Claims:

We claim:

1. Compound (III)




- 5 which is the monohydrate of the monochloride of compound (I)



2. The form of the compound of claim 1 characterized by a X-ray powder diffractogram measured at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2θ value ± 0.2°: 9.3, 10.6, and 13.3.
- 10 3. The form of the compound of claim 1 characterized by a X-ray powder diffractogram measured at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2θ value ± 0.2°: 9.3, 10.6, 13.3, 20.7, and 23.3.
4. The form of the compound of claim 1 characterized by a X-ray powder diffractogram measured at 25°C and with Cu-K alpha 1 as radiation source displaying at least the


following reflections, quoted as 2θ value $\pm 0.2^\circ$: 9.3 , 10.6 , 11.4 , 13.3 , 20.7, 23.3 , and 26.0.

5. The form of the compound of claim 1 characterized by a X-ray powder diffractogram measured at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2θ value $\pm 0.2^\circ$: 6.8, 9.3, 10.6, 11.4, 13.3, 20.7, 23.3, 24.6, 26.0, and 27.6.
6. A pharmaceutical composition comprising pseudopolymorphic form (III) of the compound of formula (I) and optionally further pharmaceutically acceptable excipients.
7. The pharmaceutical composition of claim 6 comprising crystalline form (III) of the compound of the formula (I) mainly and no significant fractions of another form of the compound of the formula (I) and optionally further pharmaceutically acceptable excipients.
8. A crystalline form of the compound of any of claims 1 to 5 for use in the treatment and/or prophylaxis of cancer.
9. A pharmaceutical composition of any of claims 6 to 7 for use in the treatment and/or prophylaxis of proliferative disorders, such as cancer and tumor diseases.
10. Use of a compound as defined in any of claims 1 to 5 for the manufacture of a pharmaceutical composition for the treatment or prevention of proliferative disorders, such as cancer and tumor diseases.
11. Use of a compound as defined in any of claims 1 to 5 for the manufacture of a tablet which is physically and chemically stable.
12. A method of treating or preventing proliferative disorders, such as cancer and tumor diseases in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of the compound as defined in any of claims 1 to 5.
13. A process for producing the crystalline form (III) of the compound of formula (I) comprising the step of allowing the compound of formula (I) to react, by dissolution or suspension of the compound of formula (I) in an inert solvent and addition of an acid or acid precursor.
14. The process of claim 13, wherein the compound of formula (I) is allowed to react by dissolution or suspension of the compound of formula (I) in THF or EtOH and water, and addition of HCl.
15. The process of claim 14, wherein the compound of formula (I) is produced by allowing a compound of formula (VII)



(VII)


to react in the presence of THF and water with K_2CO_3 and a palladium catalyst with a compound of formula (VIII)



5

(VIII).


16. The process of claim 15, wherein the compound of formula (VII) is produced by allowing a compound of formula (V) to react



10

(V)


with a compound of formula (XIII)



(XIII)

with paraformaldehyde in the presence of an acid to an thereby producing a compound of formula (VI),

15




(VI)

and then allowing the compound of formula (VI) to react with a bromination agent.

5


17. The process of claim 16, wherein the compound of formula (V) is produced by allowing a compound of formula (IV) to react



(IV)

10


with an acid thereby producing a compound of formula (XXII),



(XXII)

15

and then allowing (XXII) to react with methanol in the presence of a base, thereby producing a compound of formula (XXIII),




(XXIII)

20


and then allowing (XXIII) to react with formamidine acetate and a base.

18. The process of claim 17, wherein the compound of formula (IV) is produced by allowing a compound of formula (X)



(X)


to react with Boc-NH-NH₂ to form a compound of formula (XI)



5

(XI)


which is allowed to react with ClSO₂NCO to form a compound of formula (XII)



(XII)

which is, in turn, allowed to react with N-bromosuccinimide to form a compound of formula (IX)

10



(IX)

which is allowed to react with metal organic reagents, preferably with methyl magnesium bromide and butyl lithium, in addition to paraformaldehyde to form a compound of formula (IV).

15




FIG. 1: XRPD of Monohydrate (A)




FIG. 2




FIG. 3




FIG. 4

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2020/051884

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D487/04 A61K31/53 A61P35/00
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
C07D
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2013/087578 A1 (BAYER PHARMA AG [DE]; BAYER IP GMBH [DE]) 20 June 2013 (2013-06-20) cited in the application examples 1-2	1-18
A	MARIE-PIERRE COLLIN ET AL: "Discovery of Rogatinib (BAY 1163877): a pan-FGFR Inhibitor", CHEMMEDCHEM, vol. 13, no. 5, 6 March 2018 (2018-03-06), pages 437-445, XP055523635, DE ISSN: 1860-7179, DOI: 10.1002/cmdc.201700718 abstract	1-18

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 4 March 2020	Date of mailing of the international search report 17/03/2020
-------------------------------------------------------------------------------	----------------------------------------------------------------------

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Gettins, Marc
----------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2020/051884

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2013087578	A1	20-06-2013	AR 089207 A1 06-08-2014
			AU 2012350750 A1 12-06-2014
			AU 2017206140 A1 03-08-2017
			AU 2019204255 A1 04-07-2019
			BR 112014014531 A2 06-08-2019
			CA 2859133 A1 20-06-2013
			CL 2014001547 A1 24-10-2014
			CN 104245700 A 24-12-2014
			CO 7030961 A2 21-08-2014
			CR 20140288 A 14-07-2014
			CU 20140065 A7 27-11-2014
			CU 20160039 A7 31-08-2016
			CY 1118112 T1 28-06-2017
			DK 2791140 T3 19-09-2016
			DO P2014000127 A 15-08-2014
			EA 201400707 A1 28-11-2014
			EP 2791140 A1 22-10-2014
			ES 2591203 T3 25-11-2016
			GT 201400113 A 25-08-2015
			HK 1205123 A1 11-12-2015
			HR P20161130 T1 18-11-2016
			HU E029582 T2 28-03-2017
			IL 232611 A 29-05-2017
			JO 3295 B1 16-09-2018
			JP 6050829 B2 21-12-2016
			JP 2015500307 A 05-01-2015
			KR 20140103328 A 26-08-2014
			LT 2791140 T 10-10-2016
			ME 02517 B 20-02-2017
			MX 367158 B 07-08-2019
			NZ 625073 A 29-07-2016
			PE 20141855 A1 26-11-2014
			PH 12014501355 A1 22-09-2014
			PL 2791140 T3 31-08-2017
			PT 2791140 T 20-09-2016
			SG 11201402325Q A 26-09-2014
			TN 2014000255 A1 30-09-2015
			TW 201339162 A 01-10-2013
			UA 116768 C2 10-05-2018
			US 2013158000 A1 20-06-2013
			US 2014336173 A1 13-11-2014
			US 2019016724 A1 17-01-2019
			UY 34484 A 31-07-2013
			WO 2013087578 A1 20-06-2013
			ZA 201405140 B 26-04-2017